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CHAPTER 1
Deep Vein Thrombosis Associated with 
Central Venous Catheters – a Review
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Introduction
Central venous catheters (CVCs) are fre-
quently used in patients for a variety of indi-
cations such as cancer treatment, diagnostic
monitoring, parenteral nutrition, haemodialy-
sis, cardiac pacing, and administration of flu-
ids, blood products or medication.1 The ben-
efit derived from a CVC may be offset by
thrombosis and associated complications,
such as pulmonary embolism (PE), CVC dys-
function, infection or loss of venous access.
In the long term patients with thrombosis
may suffer from a post thrombotic syn-
drome.1,2
The CVC-related thrombosis is an issue
of importance to many clinicians, and insight
into the different aspects is crucial to guide
decisions in treatment in often vulnerable
patients in daily practice. In medical litera-
ture, there is a lack of uniformity and uncer-
tainty about several entities of CVC-related
thrombosis. Firstly, two types of CVC-relat-
ed thrombosis must be clearly distinguished:
i.e. clinically manifest and subclinical throm-
bosis. Furthermore, the type of thrombosis
and the incidence is defined by the diagnostic
strategy in patients with a CVC. Secondly,
anticipation of the risk of CVC-related
thrombosis and the identification of certain
“high-risk” patients, who are prone to devel-
op thrombosis and secondary complications,
is essential to initiate early preventive meas-
urements such as prophylactic anticoagula-
tion. The need for anticoagulant prophylaxis
is however still a subject of discussion.3,4
Finally, for the treatment of established
CVC-related thrombosis, several therapeutic
options were evaluated in literature. General
recommendations of anticoagulant treat-
ment, and whether CVC removal is neces-
sary, or not, is warranted.
The primary aim of this review is to
describe the diagnostic methods and their
performance, the incidence and risk factors,
complications, prevention and treatment of
CVC-related thrombosis from a practical and
clinical point of view. English medical litera-
ture studies were retrieved by an extensive
Medline search (Pubmed®) and bibliogra-
phies of the obtained studies were cross-
checked where necessary. For each subject,
only those studies with the strongest level of
evidence, as defined and discussed in the
subsequent paragraphs, were selected and
reviewed.
Chapter 01
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Diagnosis of
CVC-related thrombosis
In view of diagnosis of CVC-related
thrombosis, two types of thrombosis can be
distinguished; clinically manifest thrombosis
and subclinical thrombosis. Clinically mani-
fest thrombosis is defined as thrombosis
objectified by diagnostic imaging (ultra-
sound, venography) upon overt symptoms
and signs, such as pain or tenderness,
warmth, swelling or edema, bluish discol-
oration or visible collateral circulation.
Subclinical thrombosis, defined as thrombo-
sis in the absence of signs and symptoms, is
demonstrated by screening diagnostic imag-
ing. Most thrombotic events associated with
CVCs remain subclinical, or complications
such as PE are the first presenting symp-
tom.5-7 
Radiologically, thrombosis can have a
typical appearance of enveloping sleeve 
surrounding the CVC (Fig. 1) or be charac-
terized by mural thrombosis adherent to the
venous vessel wall.8 Mural thrombosis, pres-
ent in approximately 30% of patients with
CVCs, may cause subtotal stenosis (Fig. 2) or
occlusion of the venous lumen and lead to
clinically manifest thrombosis or associated
complications.6 Mural thrombosis is often
found near the entry site of the CVC into the
vessel or at the junction of large veins,
although it may be extended or located into
adjacent venous segments or the right atrium.
In the diagnostic work-up of CVC-relat-
ed thrombosis, diagnostic imaging upon a
clinical suspicion of thrombosis is mandato-
ry. A diagnosis based solely on clinical symp-
toms and signs of thrombosis is non-specif-
ic, as in deep vein thrombosis (DVT) of the
leg. In only about a third to a half of all
patients in whom thrombosis is clinically sus-
pected, the diagnosis is confirmed.9-11
Contrast venography is widely recognized
as the reference standard in the diagnosis of
thrombosis.12 However, ultrasound is most
often used clinically, because it is non-inva-
sive, does not expose to ionizing radiation,
can easily be performed at the bedside and is
well accepted by patients. In modern ultra-
sonography, real time gray-scale images (B-
mode) are obtained and the criteria of non-
compressibility (compression ultrasound)
and direct visualization of thrombotic mate-
rial in the venous lumen can be used to
establish the presence, or absence, of throm-
bosis. Besides, real time changes in vessel
diameter due to respiration may detect occlu-
sive thrombosis more centrally located. In
addition, Doppler techniques can add the
advantage of evaluation of blood-flow. With
pulsed Doppler signals added to gray scale
imaging (duplex ultrasound) qualitative and
quantitative information of blood flow can
be obtained. Color Doppler flow imaging
(CDFI) displays blood flow in color in addi-
tion to gray scale imaging. A combination of
all three modalities is known as color duplex
ultrasound.
In symptomatic lower extremity DVT,
compression ultrasonography has been vali-
dated in clinical practice,13 but specifically for
thrombosis associated with femorally insert-
11
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ed CVCs no studies are available in which
ultrasound was compared to venography.
With regard to the upper-extremity DVT,
venography has high to moderate inter-
observer agreement rates (71 - 83%) and can
be used as a reference test in clinical prac-
tice.14 In several studies the diagnostic accura-
cy of ultrasound in upper extremity throm-
bosis compared with venography was
evaluated.
For the purpose of this review, we select-
ed those studies in which ultrasound was
compared to routine contrast venography in
the diagnosis of upper-extremity DVT in the
entire cohort of reported patients, and which
results were independently interpreted by
blinded observers. Overall, six studies were
retrieved (Table 1) in which patients with
CVCs were included. The reported sensitivity
of ultrasound in the diagnosis of upper
extremity DVT among these studies ranged
from 56% to 100%, whereas the specificity
ranged from 77% to 100%.10,11,15-18
Reports specifically aimed at patients
with CVCs are limited to three studies only.16-
18 Importantly, in patients with CVC-related
thrombosis, thrombosis tends to be located
more centrally than in patients with throm-
bosis not related to CVCs.4 As a conse-
quence, the diagnostic technique of ultra-
sound, and therefore the accuracy, in patients
with suspected thrombosis because of CVCs
is different than those without (history of)
CVC. In one study continuous wave Doppler
without gray scale imaging was used, a tech-
nique hardly applied nowadays.18 Applying
modern techniques, duplex ultrasound was
reported to have an excellent specificity
(100%), however the sensitivity was substan-
tially lower (56% ).17 In another study, CDFI
was found to be more sensitive (sensitivity
94%, specificity 96%).16
Summary
In summary, reliable data on the accuracy
of ultrasound in CVC-related thrombosis are
limited. In lower extremity CVC-related
thrombosis no studies are available. In upper
extremity CVC-related thrombosis specifical-
ly, only three studies are available, of which
CDFI had the best performance (sensitivity
94%, specificity 96%). In view of the advan-
tages of ultrasound mentioned, and the high
specificity, patients with clinically suspected
CVC-related thrombosis, should undergo
ultrasound initially. However, the safety of
withholding treatment in case of a negative
ultrasound in patients suspected for throm-
bosis is uncertain.19 As a consequence, in
patients with normal ultrasound additional
venography could be performed. Alternative
strategies such as serially performed ultra-
sound, spiral computed tomography (CT) or
magnetic resonance imaging (MRI) may be
useful and of potential interest, but are not
validated yet.
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Figure 1. Ultrasonic appearance of a typical en-
veloping “fibrin sheath” demonstrated
immediately after catheter removal (Jug-
ular vein)
Figure 2. Nearly occlusive mural thrombosis visu-
alised by a flow defect, detected by
colour Doppler flow imaging, just after
catheter removal
Table I. Diagnostic accuracy of ultrasound in the diagnosis of upper extremity thrombosis with routine contrast venography as the reference
standard.
Study (Reference) Patients CVC† Technique‡ Sensitivity Specificity Thrombosis-type*
Prandoni  et al. (10) n = 58 14% CUS 96% 94% Manifest
Prandoni et al. (10) n = 47 N.I. Duplex 81% 77% Manifest
Prandoni et al. (10) n = 34 N.I. CDFI 100% 93% Manifest
Baarslag et al. (11) n = 99 N.I. CDFI 82% 82% Manifest
Baxter et al. (15) n = 19 74% CDFI 100% 100% Manifest
Köksoy et al. (16) n = 44 100% CDFI 94% 96% Mixed
Haire et al. ( 17) n = 43 100% Duplex 56% 100% Mixed
Bonnet et al. (18) n = 40 100% Doppler 93% 93% Mixed
† Percentage of patients with a central venous catheter (CVC). N.I. = Not Indicated
‡ Technique: CUS = compression ultrasound; CDFI = color Doppler flow imaging.
* For definition manifest/subclinical, see text.
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Incidence and risk factors
of CVC-related thrombosis
Incidence
In numerous studies the incidence of
CVC-related thrombosis has been evaluated.
In most studies, clinically manifest thrombo-
sis was used as the primary endpoint. Among
these studies incidences ranging from 0% to
28% were reported.20,21 However, the decision
to refer for diagnostic imaging upon clinical
signs and symptoms for thrombosis lacks
uniformity and may be subjective.
A more reliable estimate is given by studies 
in which routine diagnostic screening 
(ultrasound or venography) was used in con-
secutive patients with CVCs to determine
thrombosis. For the purpose of this review
these studies are selected and summarized in
Table 2, according to the indication for the
CVC, i.e. the underlying disease and the type
of thrombosis (subclinical, clinically mani-
fest and overall).5,6,8,22-44
Overall, the reported incidences of CVC-
related thrombosis in these studies ranged
widely from 2% to 67% (Table 2). The wide
range in observed incidence may be partly
caused by different diagnostic modalities
(venography, ultrasound), the used criteria,
and patient- and CVC characteristics. On
average, a 30% cumulative incidence was
found in hospitalized patients and the overall
majority of thrombotic events remained sub-
clinical.6 The percentage of clinically mani-
fest thrombosis in these studies ranged from
0% to 12% (Table 2).
In some specific populations, such as
patients with hemophilia, prospective
(screening) studies are not available. In
cohort-studies with merely clinical manifest
thrombosis as an endpoint incidences ranged
from 0% to 3%.45 Whether in patients with
inherited bleeding disorders the risk of
thrombosis is reduced as compared to other
patients, is not known because of the lack of
large studies in which all patients were
screened systematically for thrombosis.
Risk factors
The individual risk of CVC-related
thrombosis in a patient is the result of the
interaction between patient characteristics,
i.e. inherited and acquired risk factors; and
the CVC (Fig. 3). There are numerous studies
in which risk-factor analysis of CVC-related
thrombosis was performed. For inherited
and common acquired risk factors cohort
studies were considered to represent the
highest level of evidence (level 1); case con-
trol studies as level 2. For CVC characteris-
tics, randomized trials were considered to
represent level 1 of evidence; cohort studies
as level 2.
Inherited coagulations disorders have
been reported to contribute substantially to
CVC-related thrombosis in large cohort
studies (level 1). Factor V Leiden (FVL) was
strongly associated with clinically manifest
thrombosis in patients who underwent bone
14
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marrow transplantation (n=277); i.e. 54% of
patients with FVL developed thrombosis, in
comparison to 10% of patients without (Cox
proportional hazard ratio 7.7).46 In a large
hospital population of 252 patients, the pres-
ence of FVL and prothombin G20210A
mutation increased the overall risk of CVC-
related thrombosis almost threefold.6 Two
other recent performed studies also suggest-
ed a contribution of commonly inherited
coagulations disorders.47,48 In contrast to
these studies, a case control study (level 2)
reported no increased prevalence of FVL in
patients with CVC-related thrombosis as
compared to the general western popula-
tion.49 In children, similar risk estimates as in
adults have been reported. In cohort studies,
the risk of thrombosis in FVL carriers in
pediatric patients was substantial in patients
with acute lymphoid leukemia, as well in
mixed populations.43,50,51
With regard to common acquired risk
factors of venous thrombosis there are
numerous studies of different level of evi-
dence. In cohort studies, the presence of
cancer or active cancer treatment, in both
adults and children,6,44 prior thrombo-
embolism;32 acquired (temporary) hyper-
coaguable state;43,52 and a high platelet count
at CVC insertion,53 were associated with
thrombosis. Age was also associated with
CVC-related thrombosis, the risk was higher
with increasing age, and in very young chil-
dren.24,44
Many CVC characteristics have been
associated with an increased risk of CVC-
related thrombosis. The type of CVC may be 
an important factor in the development of
CVC-related thrombosis. Catheters com-
posed of silicon or polyurethane are less
often associated with local thrombosis than
CVCs made of polyethylene.35,54,55 In addition,
the risk of thrombosis tends to increase with
the number of CVC lumina.5,56 The role of
the puncture-site of CVC insertion is still
much debated. In two randomized trails
(level 1) in intensive care unit patients inser-
tion via the subclavian route had a low risk
of thrombosis as compared to a femoral
route (0% vs. 25%, respectively 6% ).57,58 A
similar observation was found in a cohort
(level 2) study in patients with subclavian
vein CVC as compared to jugular CVCs
(11% vs. 42%).24 In both studies patients were
routinely screened by ultrasound for CVC-
related thrombosis. However, the methodol-
ogy of comparing femoral with subclavian
vein thrombosis associated with CVCs can
15
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Figure 3. Interaction of inherited, acquired risk-
factors of thrombosis with catheter
characteristics play an important role
the development of catheter-related
thrombosis.
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be debated since the technique and accuracy
of ultrasound in asymptomatic upper and
lower DVT differ. In a recent cohort study
(level 2) in children, the subclavian route had
an increased risk of thrombosis as compared
to the jugular route as assessed by a combi-
nation of routine venography and routine
ultrasound.58 In cohort studies, a left inser-
tion side has been reported to increase the
risk of thrombosis,37,53,58 and with a CVC tip
position into the subclavian or innominate
vein, thrombosis was more often observed in
comparison to a superior caval vein or right
atrial tip location.39 Additional factors in
cohort studies that have been reported to
increase the risk of thrombosis are a percuta-
neous insertion procedure, prior CVC at the
same puncture site and a prolonged stay of
the CVC for over 2 weeks.58,59
Summary
In summary, CVC-related thrombosis is a
multicausal disease. Prothrombotic factors
(e.g. FVL) and the underlying disease (can-
cer) may play an important role in the devel-
opment of CVC-related thrombosis. Some
important CVC characteristics increase the
risk of thrombosis, such as the type and
material of the CVC, vascular trauma and the
duration of stay of the CVC.
Complications
Central venous catheter-related thrombo-
sis may be associated with several complica-
tions including PE, infection of the throm-
bus, CVC dysfunction and subsequent loss
of intravenous access and post-thrombotic
syndrome or recurrent thrombosis.
Pulmonary embolism
The reported incidence of PE as a com-
plication of CVC-related thrombosis varies.
In only one study, all patients with proven
thrombosis systematically underwent screen-
ing for PE (ventilation-perfusion scan) and a
15% cumulative incidence was reported.60 In
other studies incidences of PE, using merely
clinical endpoints, varied greatly. Whereas
incidences of symptomatic PE up to 17%
have been reported, others did not observe
any PE.61,62 Pulmonary embolism associated
with CVC-related thrombosis has been
reported to be the cause of death.7,60
Screening for PE if a diagnosis of CVC-
related thrombosis is established, is usually
not mandatory, since in most patients antico-
agulant treatment is initiated, eventually with
a removal of the CVC. A firm evidence
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Table II. Incidence of catheter-related thrombosis amongst studies with routine diagnostic imaging performed in consecutive patients 
(ultrasound or venography).
Study (Reference) Population* n Technique‡ Thrombosis (manifest) Location entry-site 
Chastre et al. (22) ICU 33 V 67% (0%) Jugular vein
Durbec et al. (23) ICU 70 V 36% (0%) Femoral vein
Timsit et al. (24) ICU 208 U 33% (0%) Subclavian & Jugular vein
Wu et al. (25) ICU 81 U 56% (0%) Jugular vein
Joynt et al. (26) ICU 124 U 10% (2%) Femoral vein
Martin  et al. (27) ICU 60 U 58% (2%) Axillary vein
Stoney et al. (28) Cardiology 203 V 34% (3%) Cephalic & Jugular vein
Goto et al (30) Cardiology 100 V 23% (0%) Cephalic & Subclavian vein
Lin et al. (29) Cardiology 109 U 6% (0%) Cephalic & Subclavian vein
Antonelli et al. (31) Cardiology 40 V 28% (5%) Cephalic & Subclavian vein
van Rooden et al. (32) Cardiology 145 U 23% (2%) Cephalic & Subclavian vein
Valerio et al. (33) Oncology 18 V 33% (6%) Subclavian vein
Brismar et al. (34) Oncology 53 V 36% (unknown) Subclavian vein
Bozetti et al. (35) Oncology 52 V 28% (0%) Subclavian vein
Haire et al. (5) Haematology 35 V 63% (9%) Subclavian vein
Balesteri et al. (8) Oncology 57 V 56% (0%) Subclavian vein
De Cicco et al. (37) Oncology 95 V 66% (6%) Subclavian vein
Biffi et al. (38) Oncology 302 U 4% (2%) Subclavian & Cephalic vein
Luciani et al. (39) Oncology 145 U 12% (3%) Subclavian vein
Harter et al. (40) Oncology 233 U 2% (0%) Jugular vein
Lordick et al. (41) Haematology 43 U 30% (0%) Jugular vein
van Rooden et al. (42) Haematology 105 U 28% (12%) Jugular & Subclavian vein
Nowak-Gottl et al. (43) Pediatrics 163 U 11% (11%) Subclavian vein
Beck et al. (44) Pediatrics 93 U 18% (8%) Jugular & Subclavian & Femoral vein
van Rooden et al. (6) Mixed 252 U 30% (7%) Jugular & Subclavian vein
*Population: ICU = Intensive Care Unit
‡ Technique: V = Venography; U = ultrasound
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Infection
CVC-related thrombosis and CVC-relat-
ed infection have been reported to be associ-
ated.24,41,63,64 The pathogenesis of CVC-related
infection seems to depend on the develop-
ment of thrombosis of the CVC. Several
thrombo-proteins were shown to increase
the risk of subsequent infection.65,66 Results
from a post-mortem study in 72 patients
with a CVC at death revealed that in all
patients with CVC-related sepsis (n=7) mural
thrombosis after a CVC was present, out of
a total number of 31 patients with thrombo-
sis.63 In a study in 265 critically ill patients the
risk of infection and sepsis was 2.6-fold
increased in patients with CVC-related
thrombosis.24 In 43 patients undergoing
intensive chemotherapy, 13 patients had
objectified subclinical thrombosis of whom
12 developed infection.41
In addition, CVC-related infection may
also increase the risk of subsequent clinically
manifest thrombosis. In one study CVC-
related infection increased the risk of throm-
bosis (24%) markedly in comparison to those
without infection (3%) (relative risk 17.6).64
In the presence of CVC-related infection,
it may be useful to screen patients for throm-
bosis with ultrasound, even in the absence of
other clinical overt signs and symptoms.
Whether such a strategy is clinically benefi-
cial, improves clinical outcome, and is cost-
effective should be further investigated.
Early CVC removal 
and dysfunction
The CVC dysfunction due to clot forma-
tion may occur due to obstruction within the
CVC lumina, or occlusion due to an envelop-
ing sheath obstructing the CVC luminal tip.
Clot formation of the CVC has been identi-
fied as the principal cause of CVC dysfunc-
tion in prospective follow-up studies. In a
study in 85 CVCs placed for haemodialysis,
16 (19 %) clot formation occurred leading to
CVC malfunctioning requiring removal of
the CVC in all cases. 67 In another study in 92
CVCs inserted for haemodialysis, 11 CVCs
had to be removed because of catheter com-
plications.68 In six (55%) of these cases,
occlusion due to clot was the major reason
for removal of the CVC. In a study of 949
CVCs placed for ambulatory chemotherapy
in cancer patients, 152 (18%) of the catheters
had to be removed due to complications.69 In
this study infection of the CVC was the lead-
ing cause of removal of the CVC, 47 (31%)
out of 152 CVCs, but also 38 (25%), had to
be removed due to CVC-related thrombosis
or dysfunction due to clot. In a large study
based on the Strategic Health Care Programs
National Database, CVC complications that
occurred in 45.333 CVCs used in an outpa-
tient setting in a 17-month period between
1999 and 2000 were evaluated.70 In 1.871
CVCs dysfunction occurred, and in 511 (27
%) cases dysfunction occurred as a conse-
quence of clot formation. In this study dif-
ferent types of catheters were shown to carry
a different complication rate but thrombosis
18
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Table III. Studies in which the benefit from anticoagulant prophylaxis for catheter-related thrombosis was evaluated. Studies were classified into
three categories: Randomized controlled trials with routine mandatory diagnostic imaging 2. Randomized controlled trials with clinically
manifest thrombosis or associated complications, and 3. Observational studies with clinically manifest thrombosis or associated compli-
cations.
Randomized controlled trials – Mandatory diagnostic imaging
Study (Reference) Population n Intervention Patients Controls Endpoint
Bern et al. (74) Oncology 82 Warfarin 1mg 9.5% 42% Mandatory venogram
Monreal et al. (75) Oncology 29 Dalteparin 2500 IU 6% 62% Mandatory venogram
Abdelkefi et al. (76) Haematology 128 UFH (100 IU/kg) 1.5% 12,6% Mandatory ultrasound
Brismar et al. (34) Nutrition 49 UFH (5000 IU q 6h) 21.7% 53.8% Mandatory venogram
Rugerio et al. (80) Nutrition 34 UFH (1000 IU/L) 53% 65% Mandatory venogram
Fabri et al. (81) Nutrition 46 UFH (3000 IU/L) 8.3% 31.8% Mandatory venogram
Fabri et al. (82) Nutrition 40 UFH (3000 IU/L) 0% 0% Mandatory venogram
Mackoviak et al. (79) Nutrition 37 UFH (1U/ml) 17.6% 15.6% Mandatory venogram
Pierce et al. (78) Pediatr. Crit. Ill 209 UFH bonded CVC 8% 0% Mandatory ultrasound
Massicotte et al. (77) Pediatr. Oncology 158 Reviparin 30-50 IU/kg 14.1% 12.5% Mandatory venogram
Randomized controlled trials – Clinical endpoints
Study (Reference) Population n Intervention Patients Controls Endpoint
Heaton et al. (84) Haematology 88 Warfarin 1 mg 17.7% 11.6% Including PE & malfunction
Anderson et al. (85) Oncology 255 Warfarin 1 mg 4.6% 4% CMT only
Reichardt et al. (83) Oncology 425 Dalteparin 5000IU 3,4% 3,7% CMT only
Cohort studies - Clinical endpoints
Study (Reference) Population n Intervention Patients Controls Endpoint
Boraks et al. (86) Oncology 223 Warfarin 1 mg 5% 13% CMT only
Lagro et al. (87) Oncology 323 Nadroparin 2850IU 7% 6% CMT only
Lagro et al. (87) Oncology 323 Nadroparin 5600IU 8% 6% CMT only
UFH = unfractionated heparin; CMT = clinically manifest thrombosis; PE = pulmonary embolism.
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was the most commonly reported cause of
CVC dysfunction for peripherally and cen-
trally inserted CVC with implantable ports.
Post-thrombotic syndrome 
and recurrent thrombosis
The incidence of the post-thrombotic
syndrome, characterized by venous hyperten-
sion, swelling of the extremity and pain,10 has
been studied in patients without a CVC who
experienced an episode of deep vein throm-
bosis. In such patients, an incidence of up to
80% of the post-thrombotic syndrome has
been reported.71 However, data on post-
thrombotic syndrome occurring as a sequela
of CVC-related thrombosis are scarce and
show contradictory results. Hingorani et al.
reported a cumulative incidence of 4%,
whereas Hicken et al. found a much higher
cumulative incidence of 50%.63,72 In a
prospective study of a large group of 405
children with various diseases who all devel-
oped thrombosis of the upper or lower
extremity, 244 (60 %) had a CVC.73 Of these
405 children, 40 % had thrombosis of the
lower and 60 % had thrombosis of the upper
extremity. Post-thrombotic syndrome was
found to occur in fifty (12%) of the 405 chil-
dren. Of the 50 children who developed a
post-thrombotic syndrome, 23 had a CVC.
In this study a CVC was not an indicator for
post-thrombotic syndrome (OR 0.59; CI95%
0.28 – 0.94). There are no reliable data con-
cerning recurrent thrombosis after an
episode of proven CVC-related thrombosis.
Summary
In summary, PE is an understudied and
probably underdiagnosed complication of
CVC-related thrombosis and together with
infection of the thrombus a serious life-
threatening complication. In clinical practice,
an established diagnosis of infection may
render it worthwhile to screen for thrombo-
sis with ultrasound. Besides, luminal clot is
the most commonly reported cause of
catheter malfunctioning and removal of the
catheter. The post-thrombotic syndrome
causes severe morbidity, however, whether a
CVC is an important risk factor is unclear.
Prevention
In several studies among different patient
populations the effectiveness of anticoagu-
lant prophylaxis was evaluated. Basically,
three groups of patients were distinguished:
1. Patients with haematological or solid
tumor malignancies and 2. Non-cancer
patients (usually patients with parenteral
nutrition) and 3. Critically ill patients. For the
purpose of this review three types of studies,
according to level of evidence, are discussed
subsequently (Table 3): 1. Randomized con-
trolled trials (RCTs) with routine diagnostic
imaging (venography or ultrasound) to define
CVC-related thrombosis as an endpoint.
Interpretation of data was blindly assessed.
(level 1); 2. Randomized controlled studies
(double blind) with clinically manifest throm-
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bosis (or associated complications) as the
primary endpoint (level 2) and 3.
Observational studies which evaluated rou-
tine implementation of anticoagulant pro-
phylaxis in a cohort of consecutive patients
compared to historical controls without 
(level 3). Adult and pediatric populations are
discussed separately.
Randomized controlled trials 
with routine diagnostic imaging
Three RCTs in which routine diagnostic
imaging was used were performed in adult
cancer patients, two in pediatric popula-
tions,74-78 and five in patients receiving par-
enteral nutrition.34,79-82 
Cancer patients. In cancer patients with
subclavian CVCs, Bern et al. studied the ben-
efit of a randomly allocated fixed low dose
warfarin (1 mg once daily orally) compared
to controls without.74 Among patients on
warfarin a substantially lower frequency of
CVC-related thrombosis, as demonstrated by
venogram, was observed (9.5% vs. 42% in
controls). Monreal et al. observed a similar
benefit from a low molecular weight heparin
(LMWH) (Dalteparin 2500 IU subcutaneous-
ly) in cancer patients with subclavian inserted
Port-a-Caths®.75 In patients on Dalteparin a
6% rate in thrombosis was observed by rou-
tine venogram, as compared to 62% in
patient without. In a recent study in 128
haemato-oncology patients a benefit from
continuously administered unfractionated
heparin (UFH) (100 IU/kg/daily) was
observed.76 In the heparin group a 1.5% of
patients were diagnosed with thrombosis by
routine ultrasound, in the controlgroup
12.6%. There were three events of severe
bleeding in the heparin group, as compared
to two in the controlgroup (p=NS).
Combining the results of Monreal et al. and
Abdelkefi et al. revealed a clear benefit from
heparin as compared to placebo in adult can-
cer patients (RR 0.11; CI95% 0.03-0.45).
In a study of 158 children with haemato-
logical malignancies no substantial benefit
was obtained with a LMWH as prophylaxis.77
A total of 14% (11 of 78) of patients on
LMWH and 13% (10 of 80) in control
patients got thrombosis. In critically ill chil-
dren, the effect of a heparin bonded catheter
has been evaluated to reduce the risk of
thrombosis.78 A significant reduction in
thrombosis from 8 of 103 (8%) to 0 of 97
was observed.78 
Non-cancer patients/parenteral nutrition. In
patients who received parenteral nutrition,
only the benefit of UFH in various dosages
added to the infusate has been assessed
(Table 3). The statistically power of these
studies was however limited, due to the small
number of patients of each study.
Combining the results of these studies, a
trend in risk reduction of thrombosis by
adding UFH to the infusate was calculated
(RR 0.6; CI95% 0.34-1.06).
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Randomized controlled trials
with clinical endpoints
Cancer patients. In RCTs with clinically
manifest thrombosis as a primary endpoint
no clear benefit from anticoagulant prophy-
laxis was noticed in all three available studies
(Table 3).83-85 Remarkably, the absolute risk of
clinically manifest thrombosis in the control
group without anticoagulant prophylaxis was
low in all these studies (4%), which might
explain the lack of statistical power of these
studies. The reason for the discrepancy with
observational studies with incidences of up
to 13% (Table 2) is unclear, but may be
caused by selection of patients or referral cri-
teria for diagnostic imaging. There have been
no studies in non-cancer patients or critically
ill patients or pediatric patients in this cate-
gory of studies.
Observational studies
Cancer patients. In cancer patients two
cohort studies were performed which evalu-
ated the effect of LMWH (two regimens) or
a fixed low dose warfarin on CVC-related
thrombosis. (Table 3).86,87 In a study among
haematology patients a fixed low dose war-
farin (1 mg orally) revealed a 5% clinically
manifest thrombosis, as compared to 13% in
historical controls without.86 In another study
with retrospective controls, a 7- (2850 IU)
and 10- day (5700 IU) course of a LMWH in
haematology patients was analyzed. Overall,
there was no difference in the cumulative
incidence of clinically manifest thrombosis
between the groups who received
Nadroparin (7% and 8% respectively) and
those without (6%).87 However, in this study
most thrombotic events occurred after stop-
ping prophylaxis while the CVC remained in
place. It is unknown whether a prolongened
course would have been effective.
Combining the results of RCT and
cohorts-studies, neither an effect of warfarin
or heparin was calculated, with regard to the
risk of clinically CVC-related thrombosis.
(warfarin: RR 0.72; CI95% 0.27-1.9/ heparin
0.92; CI95 0.57-1.49).
In order to reduce CVC the risk of intra-
luminal clotformation or dysfunction flush-
ing or locking CVCs with UFH is performed
routinely in many clinics. Whether such strat-
egy is more beneficial as compared to saline
is unsure. Currently there are no reliable data
addressing this theme with clearly defined
endpoints including routine assessment by
contrast linogram, ultrasound or venography,
response-rate to subsequent thrombolysis
and safety.
Summary
In summary, the risk of thrombosis may
be reduced by applying routine anticoagulant
prophylaxis in patients with CVCs in cancer
patients. However, a clear benefit was only
demonstrated in cancer patients who under-
went mandatory diagnostic imaging, includ-
ing risk reduction of subclinical events. It is
therefore debatable whether routine imple-
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mentation of prophylaxis for CVCs is war-
ranted. Besides, the safety of anticoagulant
prophylaxis, a matter of serious concern
especially with regard to patients with cancer,
has not been studied well. In a recent survey,
it was reported that a major reason for clini-
cians not to comply with consensus guide-
lines was the risk of bleeding due to throm-
bocytopenia, which presumably outweighed
the risk of thrombosis, particularly in
patients with cancer.88-90 In this view, individ-
ualized strategies upon allocation of risk
assessment in certain vulnerable patients
with CVCs and a high risk of thrombosis,
such as those with (chemotherapy induced)
thrombocyptopenia, might be potentially
useful to guide decisions on anticoagulant
prophylaxis.
In non-cancer patients or critically ill
patients no clear benefit from anticoagulant
prophylaxis was observed. Available data
consisted of small studies. With the improve-
ment of CVC material no definite recom-
mendations in these groups of patients can
be made, until a large interventions study
becomes available.
In critically ill children one study showed
a risk reduction of CVC-related thrombosis
using heparin bonded CVCs. These CVCs
might be a safe alternative to systemic pro-
phylactic anticoagulation, and this needs to
be evaluated in other populations in need for
short term catheterization.
Treatment
For the treatment of CVC-related throm-
bosis, various options are available. Antico-
agulant treatment, removal or replacement of
the CVC, or thrombolytic therapy may be
used after a diagnosis of thrombosis is estab-
lished. In this review randomized controlled
intervention-trials evaluating the recurrence
rate of thrombosis and complications, and
safety of therapy are considered most con-
vincingly (level 1), cohort studies as level 2,
case series as level 3.
Currently, no randomized trials have
appeared in the literature. In one cohort
study, 112 cancer patients with CVC-related
thrombosis, a diversity of therapeutic inter-
ventions (several anticoagulation strategies
with or without CVC removal) were shown
not to result in major differences in clinical
outcome.61 Treatment consisted of anticoag-
ulation (n=39), anticoagulation with CVC
removal or replacement (n=22), CVC
removal or replacement (n=32), other thera-
py (n=7) or no therapy (n=8). In no patients
recurrent thrombosis or secondary complica-
tions or death of unknown cause occurred
within two weeks of diagnosis, while in four
patients with CVC replacement only symp-
toms of edema were persistent. In a prospec-
tive case-series of 46 outpatients with upper
extremity DVT, in whom 16 (35%) had a
CVC showed that LMWH (Dalteparin 200 a-
nti-Xa IU/kg) for a minimum of five days
together with oral anticoagulants was shown
to be safe and effective.91 Evaluation after 12
weeks showed one recurrent thrombosis
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(2%), no secondary complications of and
one major bleeding event (2%). However,
seven patients died, all presumably to under-
lying disease. Another study evaluated 36
patients with proven thrombosis of the
upper extremity, mostly related to CVCs, up
to one year after the diagnosis. With LMWH
followed by oral anticoagulants (6 months),
no recurrent thrombosis or secondary com-
plications were noted. Nine patients died,
presumably due to underlying disease
(25%).92
A number of non-randomized studies of
thrombolytic therapy in catheter related
thrombosis have been carried out.93-96 In a ret-
rospective analysis of 95 patients with an
upper-extremity DVT of whom 62 patients
were treated with anticoagulants and 33 with
systemic thrombolysis, it was shown that in
21 % of the patients, bleeding complications
were observed after thrombolysis compared
to no complications in the group of anticoag-
ulants only.97 Besides, in the long term no
clinical differences with regard to recurrent
thrombosis and post-thrombotic syndrome
were observed between thrombolysis and
anticoagulation.
For the treatment of fibrin sheaths or
luminal occlusion which can lead to CVC
dysfunction, the first choice of therapy is
local thrombolytic therapy with low dose tis-
sue plasminogen activator,98,99 or uroki-
nase.100,101 After 2-hour treatment with 2 mg
per 2mL recombinant tissue plasminogen
activator (Alteplase®), function was restored
to 74% in the alteplase arm and 17% in the
placebo arm (P < 0.0001 compared to place-
bo).98 After another dose (2mg per 2mL),
function was restored in 90% of patients.
There were no serious study-drug-related
adverse events, no intracranial hemorrhage,
no major hemorrhage, and no embolic
events.98 Similar results were confirmed in a
large randomized trial in over 1000 patients.99
Summary
In summary, the treatment of CVC-relat-
ed thrombosis is controversial. There are no
randomized designed studies on the best
treatment of CVC-related thrombosis, but in
most cohort studies anticoagulant therapy is
given. The necessity to remove the CVC
depends on the underlying diagnosis and
need for vascular access. There is a definite
need for well designed studies evaluating the
optimal treatment in CVC-related thrombo-
sis. Due to the high rate of complications
during systemic thrombolysis, this therapy
should be reserved to life- or extremity-
threatening venous thrombosis.
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Objective of the Thesis
Central venous catheters (CVCs) are fre-
quently used in patients for a variety of indi-
cations such as cancer treatment, diagnostic
monitoring, parenteral nutrition, haemodialy-
sis, cardiac pacing, and administration of flu-
ids, blood products or medication. The bene-
fit derived from a CVC may be partially
offset by thrombosis and associated compli-
cations, such as pulmonary embolism, CVC-
related infection, CVC dysfunction or loss of
central venous access. In the long term
patients with thrombosis may suffer from a
post thrombotic syndrome.
CVC related-thrombosis is an issue of
importance to many clinicians of several spe-
cialties. Knowledge of the risk of thrombo-
sis in patients who undergo catheterization,
secondary complications and early identifica-
tion and anticipation of thrombosis may be
crucial in daily clinical practice.
The first aim of this thesis was to assess
the incidence and contribution of genetic
(Factor V Leiden, Prothrombin G21020A)
and common acquired risk-factors (e.g. histo-
ry of venous thrombosis) to CVC-related
thrombosis in a large hospital population.
Detailed knowledge of incidence and risk
factors may help clinicians in decision mak-
ing about preventive measures such as pro-
phylactic anticoagulation. Therefore, in the
present study over 250 patients were includ-
ed, recruited from departments where central
venous catheterisation is frequently per-
formed (haematology, oncology, parenteral
nutrition, ICU and post-operative patients).
The contribution of common inherited risk
factors in blood coagulation (factor V
Leiden, prothrombin G20210A) and com-
mon acquired risk factors in venous throm-
boembolism was assessed (Chapter 3). In
addition, the risk of upper-extremity deep
vein thrombosis in patients with permanent
pacemaker leads was assessed within the first
year after implantation, and assessment of
established risk factors in venous throm-
boembolism was performed (Chapter 4).
The second aim of this thesis was to
evaluate the possibility of early identification
of patients, who already have a CVC in situ,
with a high risk of clinically manifest throm-
bosis. In this analysis, over 100 haemato-
logy patients who underwent intensive
chemotherapy (cumulative incidence of
CVC-related thrombosis in this population:
13%) were carefully monitored. We evaluated
whether screening for subclinical thrombo-
sis, performed by ultrasound (once weekly),
could predict subsequent clinically manifest
thrombosis (Chapter 5). In addition, we
assessed whether, and to what extend, rou-
tine surveillance cultures of CVC lock fluid
could predict or exclude clinically manifest
CVC-related thrombosis later in follow-up
(Chapter 6).
Finally, we investigated the clinicians’ per-
ception of risk of CVC-related thrombosis
and his (or her) compliance with prophylactic
anticoagulation by means of a nation-wide
survey (Chapter 7).
In Chapter 8 a summary is given and the
results of this thesis are discussed and sug-
gestions for future developments are given.
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Abstract
Introduction. The purpose of this study was to assess the incidence of central venous
catheter-related thrombosis and the contribution of two common inherited coagulation disor-
ders (factor V Leiden, prothrombin G20210A mutation) to this complication in a large hospi-
tal population.
Patients and Methods. In a prospective setting, patients were assessed daily for signs and
symptoms suggestive for thrombosis. Routine ultrasound was performed weekly in all patients
until CVC removal. Ultrasound examinations were stored on videotape and assessed by two
blinded observers. In case of clinically suspected thrombosis, physicians followed routine
diagnostic and therapeutic procedures. In all patients the presence of factor V Leiden and
prothrombin G20210A mutation and other potential risk factors were assessed.
Results. In 252 consecutive patients the cumulative incidence of central venous catheter-
related thrombosis was 30% (clinically manifest thrombosis: 7%). The relative risk of factor V
Leiden or prothrombin G20210A mutation for thrombosis was 2.7 (CI95% 1.9 - 3.8).
In addition, a personal history of venous thrombosis was associated with central venous
catheter-related thrombosis, whereas the severity of thrombosis was affected by the absence
of anticoagulants and the presence of cancer.
Conclusions. Thrombosis is frequently observed after central venous catheterization.
Common inherited abnormalities in blood coagulation contribute substantially to central
venous catheter-related thrombosis. In view of physicians’ reluctance of prescribing prophy-
lactic anticoagulant treatment in vulnerable patients, the a priori determination of common
inherited and acquired risk factors may form a basis to guide these treatment decisions.
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Introduction
A central venous catheter (CVC) is com-
monly used for a variety of indications.1 The
benefit derived from these devices can be
offset by thrombosis, which may be compli-
cated by pulmonary embolism (PE) and CVC
dysfunction.2-4 Often, thrombosis may force
premature CVC removal, which requires the
insertion of a new CVC with the associated
risk of complications (e.g. pneumothorax),
and the need for anticoagulant treatment
with associated bleeding risk.
Reliable estimates of the incidence of
CVC-related thrombosis among a large hos-
pital population are lacking. Besides, in con-
trast to a large number of studies on the
association of factor V Leiden (FVL) and
prothrombin G20210A mutation with deep
vein thrombosis (DVT) of the leg and PE,5
studies in which the relation of these risk
factors with CVC-related thrombosis is
investigated are scarce.6-9 Such data are rele-
vant, since they may indicate differences in
the thrombotic risk in patients who need to
undergo central venous catheterization.
Moreover, it may assist clinicians in their
decisions on anticoagulant prophylaxis.10
In a prospective setting we carefully
assessed the incidence of CVC-related
thrombosis in patients undergoing catheteri-
zation via the jugular or subclavian vein. We
determined the contribution of the two most
common prothrombotic inherited abnormal-
ities in blood coagulation, FVL and pro-
thrombin G20210A mutation, to CVC-relat-
ed thrombosis in these patients. In addition
all patients were assessed for other potential
risk factors for CVC-related thrombosis.
Patients and Methods
Patients and study design
This prospective study was performed at
the Leiden University Medical Center
(LUMC), a university hospital, the Nether-
lands. The study protocol was approved by
our local medical ethical committee and all
participating patients gave written informed
consent. Consecutive patients, aged 16 years
or older, with a CVC in place for at least 48
hours were considered eligible to participate
in the study. Central venous catheters could
be inserted via the jugular or subclavian vein.
Patients were recruited from the different
departments throughout our hospital.
Patients received a CVC for chemotherapy;
for haemodynamic or perioperative monitor-
ing, for fluid administration or for pharma-
cotherapy. Patients with abnormal ultrasound
findings (performed within 48 hours after
CVC insertion) were excluded if they had a
history of a CVC at the same insertion-site,
or a history of objectified thrombosis at the
same insertion-side, since these were regard-
ed as pre-existing thrombosis. Patients who
were unable to undergo serial ultrasound
were also excluded.
The decision to give anticoagulant pro-
phylaxis and, if so, the dosage, were at dis-
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cretion of the attending physicians. Post-
operative patients, patients who were immo-
bile or sedated, and patients with a long-term
CVC (Port-a-cath®), who received prophy-
lactic doses of Nadroparin subcutaneously
in a dosage between 2850 IU and 7600 IU
daily were classified as “prophylactic antico-
agulant treatment”. A higher daily dosage 
of Nadroparin, intravenous unfractionated
heparin (target prolongation APTT by 2 - 2.5
fold) or oral vitamin K antagonist (target
INR: 2.0 - 4.0) were classified as “therapeutic
anticoagulant treatment”.
Monitoring and follow-up
During their admission, all patients were
examined daily by physicians for symptoms
and signs suggestive for CVC-related throm-
bosis; i.e. pain, discoloration, local swelling
or edema and visible collateral circulation.
If patients were discharged from the hospital
while their CVC was still in place, patients
were seen at the (outpatient) clinic, at least
every three to six weeks. Clinical follow-up
ended six weeks after removal of the CVC,
or one year after insertion if the CVC was
still in place. Patients with clinically suspect-
ed thrombosis were referred to our depart-
ment of Radiology for ultrasound. If no
thrombosis was objectively identified by
ultrasound, patients underwent unilateral
venography.
Separate from the clinical follow-up, all
patients were examined serially for CVC-
related thrombosis by ultrasound by one
ultrasonographer according to a standardized
protocol. During admission, ultrasound was
performed within 48 hrs after the insertion
of the CVC, and at least once a week until
CVC removal. Outpatients were examined 
by ultrasound every three to six weeks.
Ultrasound examinations were performed
bilaterally and the following venous segments
were subsequently identified: the brachial,
axillary, subclavian and jugular vein. All real-
time examinations were coded and recorded
on videotape. Recordings were assessed at
least three months after discharge of the
patient from follow-up by a panel of two
blinded observers, experienced in ultrasound
evaluation. A third expert opinion was asked
for, when needed. The outcome of the
screening ultrasound examinations were not
made known to the attending physicians
responsible for clinical follow-up, nor to
radiologists who performed ultrasound or
venography in case of clinical suspicion for
thrombosis, since it is routine clinical prac-
tice to diagnose and treat CVC-related
thrombosis based on clinical signs and symp-
toms.
Blood samples were taken from all
patients within 48hrs after catheterization.
Factor V Leiden and prothrombin G20210A
mutation and factor VIII:C (IU/dl) were
determined by standard techniques as
described previously.11-13 Factor V Leiden and
prothrombin G20210A mutation were ana-
lyzed by comparing carriers of the mutation
to homozygous wild-type individuals. Factor
VIII levels were categorized in levels over
and under the 90th percentile of the distribu-
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Table I. Baseline characteristics for 252 patients with a central venous catheter 
Mean (range) 
Age (years) 54 (16 - 88)
Height (m) 1.73 (1.47 - 2.04)
Weight (kg) 75 (43 - 140)
Body mass index (kg/m2) 25 (16 – 41)






Medical conditions 170 (67.5)
Solid tumor malignancy 39 (15.5)
Haematologic malignancy 97 (38.5)
Infectious disease 13 (5.2)
Cardiopulmonary disease 11 (4.4)
Inflammatory disease 8 (3.2)
Other 2 (0.8)
Postoperative condition 82 (32.5)
Anticoagulant treatment
No anticoagulants 107 (42.5)
Prophylactic dose‡ 127 (50.4)
Therapeutic dose‡ 18 (7.1)
Type CVC*
Single/Double lumen 61 (24.2)
Triple/Four lumen 86 (34.1)




Right side 164 (65.1)
Jugular vein 143 (56.7)
‡ For definitions, see text
*CVC = central venous catheter
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tion in this patient group. In addition, estab-
lished risk factors for venous thrombosis and
CVC characteristics were assessed in detail in
each patient.
Outcome measures
The primary endpoint in this study was
CVC-related thrombosis. Two types of
thrombosis were distinguished; clinically
manifest thrombosis and subclinical throm-
bosis. Clinically manifest thrombosis was
defined as thrombosis objectified by ultra-
sound or venography following signs or
symptoms suggestive for CVC-related
thrombosis, as noticed by attending physi-
cians. Subclinical thrombosis was defined as
thrombosis demonstrated by screening ultra-
sound in the absence of signs or symptoms.
An ultrasound diagnosis of CVC-related
thrombosis was made according to prede-
fined criteria. For veins accessible to direct
insonation, the criteria of non-compressibili-
ty, visualization of echogenic intravascular
mass and absence of respiratory phasicity
were used (jugular, axillary and subclavian
vein).14-17 For veins inaccessible to direct
insonation the criterion of mono-phasic flow
(spectral Doppler) was used (middle part of
subclavian vein, brachiocephalic and superior
caval vein) to detect occlusive thrombosis.18
Criteria for contrast venography included
an intraluminal contrast filling defect of a
venous segment or persistent non-filling of a
venous segment in the presence of collateral
circulation.19 Possible complications associat-
ed with CVC-related thrombosis, PE and
CVC dysfunction (occlusion), were carefully
noted.
Statistical analysis
Cumulative incidences for subclinical
thrombosis and clinically manifest thrombo-
sis were calculated as the number of first
events over the number of patients at base-
line. The ratios of the cumulative incidences
were the relative risks (RR). Ninety-five per-
cent confidence intervals (CI95%) were
based on standard errors for binominal dis-
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Table II. The risk of central venous catheter (CVC)-related thrombosis in the presence or absence of inherited coagulation disorders.
CVC-related thrombosis
Yes No Total
Factor V Leiden or
Prothrombin G20210A mutation
Yes 16 7 23
No 59 170 229
Total 75 177 252
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tributions. The effects of risk factors that




In the 18-month study period, 368
patients with a CVC were considered for
enrollment. Informed consent was not
obtained in 88 eligible patients. In nine
patients, the attending physician did not
allow us to recruit the patient. Fourteen
patients met one of the exclusion criteria:
unable to undergo ultrasound (n=9), an
abnormal ultrasound (performed within
48hours after CVC placement) in patients
with a history of a prior CVC at the same
insertion site (n=3), or a history of objecti-
fied thrombosis on the same side prior to
CVC insertion (n=2). Thus, 257 patients
enrolled the study protocol. In the end, five
patients were excluded from analysis: in one
patient the determination of FVL and pro-
thrombin G20210A mutation had failed, in
three patients it was not possible to perform
scheduled ultrasound due to prior hospital
discharge, and one patient withdrew
informed consent. Thus, complete data were
obtained for analysis from 252 patients. The
main characteristics of these 252 patients are
shown in Table 1.
CVC-related thrombosis
Overall, 29.8% (75 of 252) of patients
developed CVC-related thrombosis (CI95%
24.1% - 35.4%). In 18 patients (7.1%) throm-
bosis was clinically manifest, while in 57
patients (22.6 %) subclinical thrombosis was
demonstrated by routine ultrasound.
Four patients (1.6%) developed PE,
objectifively diagnosed by a high probability
ventilation perfusion scintigram (n=3) or
abnormal spiral computed tomography (CT)
(n=1). In 12 patients (4.8%) one or more
lumina of the CVC became occluded.
Pulmonary embolism and CVC occlusion
were not associated with clinically manifest
thrombosis. Subclinical thrombosis was diag-
nosed in one patient with PE and another
patient with CVC occlusion.
Risk estimates for 
CVC-related thrombosis
Seventeen patients were heterozygous
carriers of the FVL mutation (6.7%) and
another 6 patients had heterozygous pro-
thrombin G20210A mutation (2.4%). No
patient was double heterozygous or homozy-
gous. Thrombosis was diagnosed in 12 of
the 17 patients with FVL (70.6%), as com-
pared to 63 of 235 patients who did have no
mutation (26.8%) (RR 2.6; CI95% 1.8 - 3.8).
Thrombosis was diagnosed in 4 of 6
patients (66.7%) with prothrombin G20210A
mutation, whereas 71 thromboses were
detected in 246 patients (28.9%) without the
43
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mutation (RR 2.3; CI95% 1.3 - 4.2). For
patients with CVC-related thrombosis who
had at least one of both mutations the rela-
tive risk was 2.7 (CI95% 1.9 - 3.8) (Table 2).
The population-attributable risk of the muta-
tions to thrombosis was 13.4%.
The risk estimates of other factors for
CVC-related thrombosis are summarized in
Table 3. In univariate analysis, a personal his-
tory of venous thrombosis was associated
with an increased risk of CVC-related
thrombosis. If patients with an inherited
coagulation disorder were excluded from the
analysis, a personal history of a venous
thrombosis was still associated with an
increased risk of CVC-related thrombosis
(RR 2.3; CI95% 1.6 - 3.4). When the risk fac-
toranalysis was performed within the group
of patients with inherited coagulation disor-
ders (n=23) or within the different groups of
patients according to the underlyingdisease
(cancer vs. no cancer) or anticoagulant-status
(absence vs. presence), no other substantial
contributors to CVC-related thrombosis
could be identified.
With regard to clinically manifest throm-
bosis, a similar trend in relative risk was
observed for the inherited coagulation disor-
ders and a personal history of thrombosis.
Three out of 23 patients (13%) with an
inherited coagulation disorder, in all cases
heterozygous FVL, developed clinically man-
ifest thrombosis, as compared to 15 of 229
(6.6%) patients without mutation, (RR 2.0;
CI95% 0.6 - 6.4). The RR from a personal
history of thrombosis was 2.3 (CI95% 0.8 -
6.5). Other factors were also associated with
the occurrence of clinically manifest throm-
bosis. The lack of anticoagulant therapy 
was strongly associated with an increased
risk of clinically manifest thrombosis 
(RR 4.7; CI95% 1.6 - 14), especially in 
cancer patients who underwent intensive
chemotherapy. Among these patients, 14 of
98 without prophylaxis developed clinically
manifest thrombosis (14.3%), whereas no
patients among the group who received anti-
coagulants (n=35) did so.
Discussion
In a large cohort of prospectively fol-
lowed patients, we found a clear relationship
between two thrombophilic mutations, FVL
and prothrombin G20210A, and CVC-relat-
ed thrombosis. Overall, in the presence of
one of the two mutations the risk of CVC
related thrombosis increased almost three-
fold. Factor V Leiden or prothrombin
G20210A contributed to 13.4% of the
thrombotic events. In addition, a personal
history of thrombosis was associated with
CVC-related thrombosis.
Reliable data concerning the association
between inherited coagulation disorders and
CVC-related thrombosis are scarce and con-
tradictory. In a study of patients undergoing
bone marrow transplantation, a 54% fre-
quency of clinically manifest thrombosis
(seven of 13 patients) in patients who were
heterozygous for FVL was reported, whereas
in patients without mutation a 10% risk was
44
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Table III. Risk estimates for central venous catheter-related thrombosis.
Patients with thrombosis (%) Relative Risk (CI95%)
Sex Male 39/149 (26.2%)
Female 36/103 (35%) 1.3 (0.9 - 1.9)
Age (years) < 75 66/226 (29.2%)
≥ 75 9/26 (34.6%) 1.2 (0.7 - 2.1)
Body mass index (kg/m2) < 30 62/219 (28.3%)
≥ 30 13/33 (39.4%) 1.4 (0.9 – 2.2)
Personal history of venous thrombosis No 60/224 (26.8%)
Yes 15/28 (53.6%) 2.0 (1.3 – 3.0)
Active cancer treatment/ intensive chemotherapy* No 34/114 (29.8%)
Yes 41/138 (29.8%) 1.0 (0.7 – 1.5)
Major surgery / trauma** No 47/153 (30.7%)
Yes 28/99 (28.3%) 0.9 (0.6 – 1.4)
Oral contraceptives / hormone therapy No 61/218 (28%)
Yes 14/34 (41.2%) 1.5 (0.9 - 2.3)
Factor VIII: C (IU /dL)† < 290 64/227 (28.2%)
≥ 290 11/25 (44%) 1.6 (1.0 - 2.5)
Family history of venous thrombo-embolism No 64/223(28.7%)
Yes 11/29 (37.9%) 1.3 (0.8 – 2.2)
Insertion site Jugular vein 42/143 (29.4%)
Subclavian vein 33/109 (30.3%) 1.0 (0.7 - 1.5)
Type of central venous catheter Single/Double lumen 20/61 (32.8%)
Triple/Four lumen 29/86 (33.7%) 1.0 (0.6 - 1.6)
Swan-Ganz 18/69 (26.1%) 0.8 (0.5 - 1.4)
Port a cath® 8/35 (22.9%) 0.7 (0.3 - 1.4)
Other 0/1 Not calculated
Absence of anticoagulant treatment No 45/145 (31%)
Yes 30/107 (28%) 0.9 (0.6 – 1.3)
* Including all patients with haematological (n=97) or solid tumor malignancies (n=39) and two patients with a stem cell transplantation for rheuma-
toid arthritis.
** Including 82 patients with a primary postoperative condition and 17 patients with primary medical condition who became operated on in follow-
up while the central venous catheter was in place.
† FVIII levels: cut off level is the 90th percentile.
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found (26 of 264 patients). The reported rel-
ative risk (Cox proportional hazard model)
from this study was 7.7 (CI95% 3.3 - 17.9).6
In a smaller study in which 82 adult cancer
patients with CVCs were evaluated, pro-
thrombotic risk factors, including FVL, were
not substantial predictors of clinically mani-
fest thrombosis, although the data suggested
that FVL increased the risk of thrombosis.7
However, the statistical power of this study
was limited because of the small numbers of
patients with thrombosis and FVL.7
In one other study it was reported that
FVL did not contribute to CVC-related
thrombosis.8 In this case control study, the
prevalence of FVL in patients with thrombo-
sis (7.4%; two of 27 patients) was not
observed to be higher than the prevalence in
Western general population (5%). The con-
tribution of prothrombin G20210A muta-
tion to CVC-related thrombosis was not
assessed in these studies.6-8
In previous studies, clinically manifest
thrombosis was used as a primary end-
point.6-8 Due to systematic screening of our
patients, we found a total of 75 cases with
thrombosis (nearly 30%), which has clearly
enhanced the statistical power of our study.
This figure indicates that clot formation is a
common phenomenon after CVC placement,
while patients are at high risk for progression
to clinically manifest thrombosis and associ-
ated morbidity. Our results emphasize the
need for implementation of adequate pre-
vention strategies.20 Although the overall fre-
quency of CVC-related thrombosis was not
reduced by anticoagulants, the severity of
thrombosis was. Clinically manifest throm-
bosis was observed substantially more often
in patients who received no adequate 
anticoagulant prophylaxis, who were mainly
patients with active cancer treatment.
Indeed, data from randomized controlled
trials have supported the use of routine anti-
coagulant prophylaxis in patients with CVCs,
which has resulted in consensus guidelines.21-
23 However, many clinicians are reluctant to
prescribe anticoagulant prophylaxis routinely
in patients with cancer and a CVC because of
the low expected incidence of thrombosis
and the fear of hemorrhage under anticoagu-
lant prophylaxis.10,24 Recently it was reported
that only 10-20% of physicians routinely pre-
scribe anticoagulant prophylaxis.10,24
Individual risk-assessment for CVC-
related thrombosis, prior to the insertion of
a CVC, could help clinicians in making deci-
sions about prescribing anticoagulant pro-
phylaxis in vulnerable patients who have a
presumed increased risk of bleeding. From a
clinical point of view, determination of FVL
and prothrombin G20210A mutation may be
useful in such individual risk assessment,
since these risk factors can easily be deter-
mined before placement of the CVC. Future
studies in which individualized anticoagulant
prophylaxis, after determination of common
inherited and established acquired risk fac-
tors, are clearly required to assess the effec-
tiveness of such a policy.
Factor VIII levels were generally high in
our patients, reflecting the acute phase reac-
tive nature of this procoagulant factor.
Patients with the highest levels appeared to
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be at a slightly higher risk of thrombosis
which further supports a prognostic role of a
prothrombotic state in the occurrence of
CVC-related thrombosis.
In this study, all patients were examined
systematically for thrombosis with serial
ultrasound. The reported sensitivity of crite-
ria used with ultrasound in subclavian throm-
bosis ranged from 78 to 96%. 14-18 Thus the
rate of thrombosis we found in patients with
a subclavian CVC could be an underestima-
tion, but this would not have materially
affected our risk estimates for prothrombotic
abnormalities. The reported specificity of
ultrasound varied from 92 to 100%.14-18 This
precludes false labeling of patients with
genetic abnormalities. Contrast venography,
although the gold standard, is an invasive test
and serial performance for screening is not
feasible.
In conclusion, thrombosis occurs fre-
quently after central venous catheterization.
Common inherited coagulation disorders and
a personal history of thrombosis contributed
to CVC-related thrombosis and increased the
risk almost three-fold. In vulnerable patients,
the determination of these factors prior to
CVC insertion could help clinicians to decide
on anticoagulant prophylaxis. Future studies
are needed to evaluate implementation of
preventive strategies, including individual
risk-assessment and subsequent anticoagu-
lant prophylaxis of high-risk patients versus
long-term routine anticoagulant prophylaxis
in all patients.
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Abstract
Introduction. Pacemaker lead implantation may cause thrombosis, which can be associat-
ed with serious local morbidity and complicated by pulmonary embolism. Few reliable esti-
mates of the incidence of thrombosis have been reported. The contribution of established
risk factors to venous thrombosis in patients with implanted pacemaker leads is unknown.
Patients and Methods. One hundred forty-five consecutive patients underwent routine
clinical and ultrasound evaluation for thrombosis before, and 3, 6 and 12 months after, lead
implantation. Established risk factors for venous thrombosis were assessed in detail for all
patients. Clinical outcome, including clinically manifest thrombosis, pulmonary embolism,
associated pacemaker lead infection, complicated reinterventions and death was evaluated.
Results. Thrombosis was observed in 34 (23%) of 145 patients. Thrombosis did not
cause any signs or symptoms in 31 patients but resulted in overt clinical symptoms in 3
patients. The absence of anticoagulant therapy, the use of hormone therapy and a personal
history of venous thrombosis were associated with an increased risk of thrombosis. The risk
of thrombosis increased in the presence of multiple pacemaker leads compared to a single
lead.
Conclusion. Established risk factors for venous thrombosis and the presence of multiple
pacemaker leads contribute substantially to the occurrence of thrombosis associated with per-
manent pacemaker leads. Risk factor assessment prior to implantation may be useful for iden-
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Introduction
Patients who undergo implantation of a
pacemaker or defibrillator are at risk for
thrombosis associated with transvenous
leads.1,2 Thrombosis may lead to severe local
morbidity and can be a source for pulmonary
embolism (PE).3-5 Thrombosis may cause
complications associated with reinterven-
tions such as lead extraction or reimplanta-
tion, even when the thrombosis itself
remains without overt clinical symptoms.
Few reliable estimates of the risk of
thrombosis associated with permanent pace-
maker leads are available.1,6-10 Evaluation of
the contribution of established risk factors
for venous thrombosis (e.g. factor V Leiden
(FVL)) is lacking. Such data are clinically rele-
vant, because they provide insight into 
the difference in thrombotic risks among
patients prior to implantation. These data
may be used to guide subsequent anticoagu-
lant prophylaxis.
The primary aim of this study was to
assess the incidence of thrombosis, the con-
tribution of established thrombotic risk fac-
tors and the clinical outcome of thrombosis
associated with permanent pacemaker leads.
Therefore we conducted a large cohort study
in patients who underwent implantation of a
pacemaker or defibrillator.
Patients and Methods
Patients and study design
This prospective observational study was
performed at the department of Cardiology
of the Leiden University Medical Center
(LUMC), the Netherlands. The study proto-
col was approved by the institutional ethics
committee, and all participating patients gave
written informed consent.
Consecutive patients (16 years or older)
undergoing elective permanent pacemaker or
internal cardiac defibrillator implantation
were considered eligible for study participa-
tion. Transvenous leads were inserted via the
cephalic or subclavian vein in the catheteriza-
tion laboratory using standard implantation
techniques. Ultrasound evaluation was per-
formed in all participating patients within 48
hours before the insertion procedure to
detect upper limb venous stenosis or occlu-
sion. Patients with abnormal ultrasound find-
ings were excluded from the study. Patients
in whom ultrasound could not be performed
prior to the insertion or during follow-up
because of technical reasons were excluded
from the study. The decision regarding anti-
coagulant or antiplatelet therapy was made
by the attending physicians. Implantation of
pacemaker leads was not a reason to initiate
anticoagulant or antiplatelet therapy.
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Surveillance and Follow-up
Follow-up was performed clinically and
by routine scheduled ultrasound during the
first year after implantation. Clinical follow-
up was performed by attending physicians
who examined patients at the outpatient clin-
ic for symptoms and signs suggestive for
upper limb thrombosis, such as pain, discol-
oration, local swelling or edema, or visible
collateral circulation. Patients with clinically
suspected thrombosis were referred to the
Radiology department for ultrasound. If no
thrombosis was found, patients underwent
unilateral venography. In addition to clinical
follow-up, all patients were examined by 
routine ultrasound (ACUSON® XP128,
Mountain View, CA, USA) by an independ-
ent physician during the first year after
implantation, respectively at 3, 6 and 12
months post-implantation. Ultrasound was
always performed by the same ultrasonogra-
pher according to a standardized protocol.
Ultrasound examinations were performed
bilaterally and the following venous segments
were identified: the brachial, axillary, subcla-
vian and jugular vein. All real-time examina-
tions were coded and recorded on videotape
(S-VHS Sony® SVO 9500 MDP, Tokyo,
Japan). After the study ended, recordings
were assessed by a panel of two blinded
observers, experienced in ultrasound evalua-
tion. A third expert opinion was solicited in
case of disagreement.
Established risk factors for venous
thrombosis were assessed in detail for all
patients. At entry into the study, patients
were asked about their personal and family
history of venous thrombosis, use of female
hormones (oral anticonceptives, hormone
replacement therapy), anticoagulant and
antiplatelet medication. FVL, prothrombin
G20210A mutation and factor VIII levels (F
VIII: C) were determined in all patients as
described previously.11-13 At each visit patients
were asked if they had suffered from cardiac
disease (e.g. myocardial infarction or conges-
tive heart failure), active cancer, chronic
obstructive pulmonary disease, diabetes mel-
litus, inflammatory bowel disease, had under-
gone major surgery or trauma, or had recent-
ly changed medication.
Outcome measures
Two types of thrombosis were distin-
guished: clinically manifest thrombosis and
subclinical thrombosis. Clinically manifest
thrombosis was defined as thrombosis
demonstrated by ultrasound or venography
following signs or symptoms suggestive of
upper limb thrombosis. Subclinical thrombo-
sis was defined as thrombosis demonstrated
by routine scheduled ultrasound assessed by
a blinded panel, in the absence of signs or
symptoms. An ultrasound diagnosis of
thrombosis was made according to prede-
fined criteria. For veins accessible to direct
insonation, the criteria of non-compressibili-
ty (if possible and adequately performed),
visualization of echogenic intravascular mass
and absence of respiratory variation were
used (jugular, axillary and subclavian vein)14-17
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Table I. Baseline characteristics of the study patients 
Mean (Range)
Age (years) 62.4 (19 – 940)
Height (m) 1.74 (1.42 – 2.04)
Weight (kg) 78.8 (45 - 130)
Body mass index (kg/m2) 25.9 (16 – 38)
Blood pressure systolic (mmHg) 132 (230 –80)
Blood pressure diastolic (mmHg) 77 (130 –50)
Number of patients (%)
Male sex 104 (71.7%)
Caucasian race 131 (90.3%)
Current smoker 30  (20.7%)
Diabetes mellitus 23 (15.9%)
Underlying disease
Ventricular tachycardia/fibrillation 62 (42.8%)
Dilating cardiomyopathy 31 (21.4%)
Atrial fibrillation/flutter 18 (12.4%)
Atrio - ventricular block 17 (11.7%)




Internal cardiac defibrillator 75 (51.7%)
Number of implanted leads
Single lead 28 (19.3%)
Double lead 82 (56.5%)
Triple lead 35 (24.1%)
Site of Implantation
Subclavian vein 168 (56.6%)*
Cephalic vein 129 (43.4%)*
Left sided implantation 129 (89%)
Anticoagulant treatment 86 (59.3%)
Antiplatelet treatment 41 (28.3%)
* Based on the number of implanted pacemaker leads (n=297) 
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For veins inaccessible to direct insonation
the criterion of mono-phasic flow (spectral
Doppler) was used (middle part of subcla-
vian vein, brachiocephalic and superior caval
vein) to detect occlusive thrombosis.18
Criteria for contrast venography included
an intraluminal contrast filling defect of a
venous segment or persistent non-filling of a
venous segment in the presence of collateral
circulation.19 Contrast venography according
to a standardized protocol was used when
thrombosis was clinically suspected but ultra-
sound findings were normal or inconclusive.
The primary study endpoint was pace-
maker lead-related thrombosis as demon-
strated by scheduled ultrasound examina-
tion. Secondary endpoints of this study were
clinically manifest thrombosis as noticed by
attending physicians between scheduled fol-
low-up visits and possible complications of
thrombosis (PE, infection, complicated re-
interventions, death). Pulmonary embolism
was diagnosed as the presence of an high-
probability ventilation-perfusion lung-scinti-
graphy, a positive spiral computed tomogra-
phy (CT) or pulmonary angiogram, based on
overt clinical signs and symptoms. When PE
was present, ultrasound of the upper and
lower extremity was performed to identify
the possible embolism source. Device-relat-
ed infection was defined as a positive wound
or device culture (local infection) with posi-
tive blood cultures (bloodstream infection)
of identical types of micro-organisms. The
decisions to obtain microbiological cultures
was made by attending physicians based on
clinical signs and symptoms.
Statistical analysis
Cumulative incidences were calculated as
the number of first events over the number
of patients at baseline. The ratios of the
cumulative incidences were the relative risks
(RR). Ninety-five percent confidence inter-
vals (CI95%) were based on standard errors
for binominal distributions. Factors associat-
ed with thrombosis in univariate analysis
were analyzed by Mantel-Haenzel statistics,




During the study period, 179 consecutive
patients were considered for enrollment; 153
gave written informed consent (86%). Three
patients were excluded because they met one
of the exclusion criteria. Four patients were
excluded from analysis because of incom-
plete data: determination of coagulation
parameters failed in two patients, and two
patients were lost to follow-up. One patient
withdrew informed consent after the study
started. Overall, complete datasets of 145
patients were available for evaluation. Table 1
lists the baseline characteristics of the study
patients. Nineteen of the 580 recordings
(3%) were not interpretable. Both observers
agreed with regard to the diagnosis of
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thrombosis for 539 (96%) of 561 recordings
(κ = 0.83).
Incidence of thrombosis 
Overall, thrombosis was diagnosed in 34
of 145 patients, resulting in a one-year cumu-
lative incidence of 23.4% (CI95% 16.6% -
30.3%). Most thrombotic events were sub-
clinical (n=31). Thrombosis was clinically
manifest in three patients (2.1%; CI95% 0%
- 4.3%). These three patients suffered from
multiple symptoms and signs of upper limb
thrombosis, such as pain (n=2), arm edema
(n=2), discoloration (n=1) or visible collater-
al circulation (n=1). Thrombosis was diag-
nosed by ultrasound in two of the patients,
in and by additional venography in one
patient. All three events were occlusive and
confirmed by subsequent scheduled ultra-
sound.
Among the 31 patients with subclinical
thrombosis based on scheduled ultrasound,
20 events were small and non-occlusive, and
11 were occlusive. Subclinical thrombosis
that subsequently progressed to clinically
manifest thrombosis was not observed in any
patient.
Most cases of thrombosis occurred wit-
hin 3 months after implantation (n=20 of
34; 59%). Eight new events (24%) were
observed between 3 and 6 months. Six new
events (18%) were noted between 6 and 12
months. The observed risks for the different
time-intervals are summarized in Table 2. In
the three patients with clinically manifest
thrombosis, the diagnosis was made 2 weeks,
2 months, and 5 months after implantation,
respectively. The three patients were treated
with low molecular weight heparin (LMWH)
for 5 days followed by oral anticoagulants in
two patients, aiming at an INR of 2.0 to 3.0.
One patient had already received aceno-
coumarol treatment but was insufficiently
anticoagulated at time of the clinical diagno-
sis (international normalized ratio (INR) 1.4).
The leads were not extracted in any of these
three patients. In all three patients with clini-
cally manifest thrombosis, a large venous col-
lateral network was observed at the ultra-
sound twelve months after implantation.
None of the patients had clinical signs of
post-thrombotic syndrome after 7 to 12
months of follow-up.
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Table II. Observed incidence of pacemaker lead-related thrombosis assessed by routine ultrasound at different time-intervals.
Follow-up interval 3rd month 6th month 12th month
Patients before assessment 145 143 138
Available Recordings 143 138 129
Thrombosis (new events) 20 (14%) 8   (6%) 6   (5%)
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Risk factors for thrombosis 
The risk estimates for established risk
factors for venous thrombosis are summa-
rized in Table 3. In univariate analysis, a per-
sonal history of venous thrombosis, use of
female hormones, and absence of anticoagu-
lant treatment were associated with an
increased risk of thrombosis (Table 3). The
risk of thrombosis was increased in patients
with multiple (two or three) pacemaker leads
compared to a single lead (27.4% vs. 7.2%/
RR 3.8; CI95% 1.0 - 15.0). Analysis of
other factors (including those as listed in
Table 1, data not shown) did not reveal any
other contributors to the risk of thrombosis.
Congestive heart failure was inversely related
to the risk of thrombosis. This finding was
likely to be related to the protective effect of
treatment with anticoagulants in these
patients (Table 3). After multivariate analysis,
the lack of anticoagulant treatment and hor-
mone therapy still was associated with a sub-
stantially increased risk of thrombosis (Table
4). A personal history of thrombosis was
slightly associated with pacemaker lead-
related thrombosis (Table 4).
Secondary endpoints
One patient suffered from proven PE,
the source of which was unclear. Ultrasound
of the upper and lower extremities was nor-
mal. Pulmonary embolism in another patient
was clinically suspected but was not con-
firmed by diagnostic imaging (normal perfu-
sion lung scan). Ultrasound was normal in
this patient.
Two patients suffered from device-relat-
ed infections (one local, one bloodstream
infection); one of these two patients had
clinically manifest thrombosis. Fourteen
patients died during follow-up, mostly as a
result of primary cardiac disease (64%). No
deaths were related to thrombo-embolic
complications. Thirteen reinterventions
occurred during the study period. A compli-
cated reintervention was related to occlusive
thrombosis in one patient. In this patient,
lead reimplantation and positioning of a
third lead failed 1 month after an episode of
clinically manifest thrombosis because of
severe stenosis of the brachiocephalic vein.
Discussion
This study showed a substantial 23% 
one-year cumulative incidence of thrombosis
associated with permanent pacemaker lead
implantation as demonstrated by routine
ultrasound examination. The majority of the
thrombotic events occurred within the first 3
months after implantation and did not cause
any clinical symptoms.
The risk of venous abnormalities associ-
ated with pacemaker leads in prospective
studies reported in the literature ranges from
5.5 to 64 %.2, 6-10 Only one study systematical-
ly used ultrasound to specifically detect
venous thrombosis after pacemaker implan-
tation. The study reported a cumulative inci-
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Table III. Risk of pacemaker lead-associated venous thrombosis for established risk factors in venous thromboembolism.
Patients with thrombosis (%) Relative Risk  (CI95%)
Sex Male 23/104 (22.1%)
Female 11/41 (26.8%) 1.2 (0.7 – 2.2) 
Age (years) * < 71.8 22/109 (20.2%)
≥ 71.8 12/36 (33.3%) 1.7 (0.9 - 3.0)
Body mass index (kg/m2) * < 27.9 24/109 (22.0%)
≥ 27.9 10/36 (27.8%) 1.3 (0.7 - 2.4) 
History of venous thrombo-embolism No 28/133 (21.1%)
Yes 6/12 (50%) 2.4 (1.2 – 4.6)
Active cancer No 30/132 (22.7%)
Yes 4/13 (30.8%) 1.4 (0.6 – 3.2)
Major surgery / trauma No 29/129 (22.5%)
Yes 5/16 (31.3%) 1.4 (0.6- 3.1)
Hormone therapy No 28/137 (20.4%)
Yes 6/8 (75.0%) 3.7 (2.2 - 6.2)
Factor V Leiden / Prothrombin G20210A No 31/135 (23.0%)
Yes 3/10 (30.0%) 1.3 (0.5 - 3.5)
Factor VIII: C (IU/dL)* < 205.5 25/109 (22.9%)
≥ 205.5 9/36 (25%) 1.1 (0.6 – 2.1)
Family history of venous thrombo-embolism No 30/124 (24.2%)
Yes 4/21 (19.0%) 0.8 (0.3 - 2.0)
Acute myocardial infarction No 30/134 (22.4%)
Yes 4/11 (36.4%) 1.6 (0.7 - 3.8)
Congestive heart failure No 29/101 (28.7%)
Yes 5/44 (11.4%) 0.4 (0.2 – 1.0)
Chronic obstructive pulmonary disease No 27/113 (23.9%)
Yes 7/32 (21.9%) 0.9 (0.4 –1.9)
Upper limb paralysis No 33/142 (23.2%)
Yes 1/3 (33.3%) 1.4 (0.3 – 7.3)
Lack of anticoagulant treatment No 12/86 (14.0%)
Yes 22/59 (37.3%) 2.7 (1.4 – 5.0)
* The cut-off values of these parameters correspond with the 75th percentile.
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dence of pacemaker lead-related thrombosis
of only of 5.5%, 4 years after implantation.7
This study of a Chinese population evaluated
patients with single pacemaker lead only. The
reported incidence is similar to our findings
in patients with a single pacemaker lead (7%).
The risk of thrombosis was substantially
higher in patients with multiple pacemaker
leads (27%).
Other studies that used routine venogra-
phy to detect venous abnormalities after lead
implantation and those reported a higher
incidence of venous lesions of up to 64%.
The findings of these studies are difficult to
compare with our study because the studies
included the criterion of venous stenosis
using different definitions, which may have
resulted in the higher reported incidences. In
addition, the reported sensitivity of the ultra-
sound technique we used ranged from 78 to
96%.14-18 As a consequence, the incidence of
thrombosis in our patients could be underes-
timated, as ultrasound would have led to a 4
to 22% false negatives rate in our patient
group. We were aware of this issue prior to
the start of the study. However, the invasive
nature of venography made its repeated use
unacceptable in this vulnerable patient
group. Use of ultrasound would not have
affected our relative risk estimates for estab-
lished risk factors in venous thrombosis.
The presence of established thrombotic
risk factors, such as the use of oral contra-
ceptives or hormone replacement and a per-
sonal history of venous thrombosis, clearly
contributed to an increased risk of thrombo-
sis associated with permanent pacemaker
leads. Only one a small case series suggested
a relationship between oral contraceptive use
and a high risk of thrombosis associated
with permanent pacemaker leads.20
The findings of our study also suggest a
benefit from anticoagulant treatment on the
thrombosis risk. One third of our study
patients did not receive anticoagulant treat-
ment, and no randomized trials have evaluat-
ed the effect of anticoagulant prophylaxis in
such patients. A benefit of low-dose heparin
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Table IV. Risk factors for thrombosis associated with permanent transvenous pacemaker leads.
Risk Factor RR* univariate (CI95%) RR* multivariate (CI95%)
Age 1.7 (0.9 - 3.0) not performed
Personal history of thrombosis 2.4 (1.2 – 4.6) 1.8 (0.6 – 5.5) 1
Hormone therapy 3.7 (2.2 - 6.2) 3.2 (1.0 – 10.5) 2
Absence of anticoagulant treatment 2.7 (1.4 – 5.0) 2.5 (1.1 – 5.5) 2
*RR =  Relative Risk 
1 Adjusted for age and hormone therapy
2 Adjusted for age and personal history of thrombosis
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(5000 IE, 2 - 3 times daily for two weeks) in
reducing the risk of PE after pacemaker
implantation has been reported.21 A 15% rate
of PE was diagnosed by routine screening
pulmonary scintigram at day 14 in patients
who did not receive heparin, compared with
no events in the group of patients who were
given heparin prophylaxis. The source of PE
was not determined, but was believed to be
pacemaker lead-related. Based on our data,
PE as a complication is infrequently observ-
ed. The present study determined clinically
manifest PE. A “true incidence” estimate of
PE would require systematic screening of all
our patients by ventilation perfusion scan
because embolic events may not be noticed
clinically.21 This was not the primary aim of
our study and would require a different
design.
Analogously to patients with cancer and
CVCs, prophylactic doses of LMWH or a
low dose of warfarin can be studied in pat-
ients not receiving routine anticoagulation.22-
24 In our study, most events were observed
within the first 3 months after implantation,
and a short-term course of prophylactic anti-
coagulation may be sufficient. The findings
of other studies support the concept that the
thrombosis risk is substantial shortly after
implantation.9,10,21 In addition, patients who
undergo pacemaker implantations reach a
temporarily state of hypercoaguability.25
Whether these patients would benefit from
short-term prophylaxis is unknown, and
requires prospective validation.
In conclusion, this study showed a high
incidence of thrombosis may be observed in
patients with pacemaker and defibrillator
leads. Anticoagulant treatment may protect
against thrombosis. The presence of estab-
lished risk factors for venous thrombosis in
patients not undergoing anticoagulant treat-
ment may substantially increase the risk of
pacemaker lead-associated thrombosis. Use
of short-term prophylactic anticoagulants
may be warranted in these patients, but
requires prospective evaluation.
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Abstract
Introduction. Patients with a central venous catheter who receive intensive chemotherapy
or a stem cell transplantation for haematological disease are at risk for developing central
venous catheter-related thrombosis. To study the incidence of thrombosis, 105 consecutive
patients underwent serial ultrasound and we evaluated whether clinically manifest thrombosis
could be predicted by screening with ultrasound.
Patients and Methods. Patients with subclavian or jugular inserted catheters were clini-
cally assessed each day for signs and symptoms of thrombosis. Additional screening ultra-
sound was performed weekly by an independent physician in all patients until catheter
removal. Ultrasound recordings were assessed by a panel of two blinded observers. In case of
clinically suspected thrombosis, attending physicians followed routine diagnostic and thera-
peutic procedures.
Results. The overall cumulative incidence of central venous catheter-related thrombosis
was 28.6% (30 of 105 patients). Of the 30 patients with thrombosis, 26 had subclinical throm-
bosis by screening ultrasound. Nine of whom developed clinically manifest thrombosis later.
Four patients had clinically manifest thrombosis without prior abnormal ultrasound. In case
of subclinical thrombosis the risk of developing symptomatic disease increases sevenfold
(34.6% versus 5.1%).
Conclusions. Screening ultrasound may be useful to identify patients at high and low risk
for clinically manifest central venous catheter-related thrombosis.
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Introduction
Central venous catheters (CVCs) are fre-
quently used in patients undergoing intensive
chemotherapy or a stem cell transplantation
for haematological disease. The benefit
derived from these devices can be offset by
thrombosis, which may force premature
removal of the CVC and necessitates antico-
agulant treatment with associated risk of
bleeding in patients who often have throm-
bocytopenia.1 In addition, thrombosis could
lead to pulmonary embolism (PE) and also
chemotherapy may have to be postponed.2,3
Two types of CVC-related thrombosis
can be distinguished, i.e. clinically manifest
and subclinical thrombosis. For clinically
manifest thrombosis, a cumulative incidence
of 12% in patients with haematological
malignancies has recently been reported.4,5
For subclinical thrombosis, reliable estimates
are scarce in patients with haematological
disease. A cumulative incidence of 33% for
subclinical thrombosis was found in recent
studies of critically ill patients admitted to
the intensive care unit.6
The use of anticoagulant prophylaxis in
cancer patients with a CVC to reduce the risk
of thrombosis and associated complications
has been proposed in consensus guidelines,
but remains debatable.7-9 Many physicians are
reluctant to prescribe anticoagulant prophy-
laxis for the prevention of CVC-related
thrombosis due to a low expected incidence
of clinically manifest thrombosis and a pre-
sumed high-risk of bleeding in these
patients.7,8
In order to individualise anticoagulant
prophylaxis, it would be worthwhile to iden-
tify patients at high-risk for clinically mani-
fest thrombosis.5,8 Screening with ultrasound
for thrombosis before signs and symptoms
or complications become manifest, may be
potentially useful. The purpose of this study
was twofold. Firstly, we evaluated the overall
incidence of CVC-related thrombosis, clini-
cally manifest and subclinical by ultrasound,
in patients undergoing intensive chemothera-
py or a stem cell transplantation for haema-
tological disease. Secondly, we evaluated the
value of screening ultrasound findings in
predicting or excluding an event of clinically
manifest thrombosis.
Patients and Methods
This study was a prospective cohort
study performed at the department of
Haematology of the Leiden University
Medical Center (LUMC), the Netherlands.
The study protocol was approved by the
local medical ethical committee. All consecu-
tive patients, aged 16 years or older, who had
a CVC indwelling for over 48 hours, were
considered eligible to participate in the study.
All participating patients gave written
informed consent.
Patients with abnormal ultrasound find-
ings (performed within 48 hours after inser-
tion) were excluded if they had a history of a
CVC at the same insertion-site, or if they
had proven thrombosis in history at the same
67
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insertion-side. Patients who were unable to
undergo serial ultrasound were also excluded.
Central venous catheters were inserted
via the subclavian or jugular vein and were
used for administering cytotoxic drugs, sup-
porting therapy, blood products, parenteral
feeding or antimicrobial therapy. Nurses
were allowed to use the CVC to withdraw
blood for diagnostic purposes and monitor-
ing. The lumina of the CVC were rinsed
once daily with a urokinase-lock (3750 IU in
1.5cc saline) according to a local protocol.
The decision to give unfractionated heparin
intravenously (100 IU per kilogram/24 hours
continuously) for the prevention of veno-
occlusive disease of the liver was at discre-




All patients were examined serially for
subclinical CVC related thrombosis by ultra-
sound with a 7.5MHz linear transducer
(Aloka® SSD 1400, Tokyo, Japan, or 
ACUSON® XP128, Mountain View,
CA, USA). Ultrasound was performed at
least once a week until CVC removal, always
by one ultrasonographer according to a stan-
dardised protocol. Examinations were per-
formed bilaterally and the following venous
segments were identified subsequently: the
brachial, axillary, subclavian, and jugular vein.
All real-time examinations were coded
and recorded on videotape (S-VHS, Sony®
SVO-9500MDP, Tokyo, Japan). Recordings
were assessed at least three months after dis-
charge of the patient from follow-up by a
panel of two blinded observers that were
experienced in ultrasound evaluation. In case
of disagreement between these two, a third
expert-opinion was sought. The outcome of
the ultrasound examinations were not made
known to the attending physicians responsi-
ble for clinical follow-up, or to the radiolo-
gists who performed ultrasound or venogra-
phy in case of clinical suspicion of
CVC-related thrombosis, as it is routine clin-
ical practice to diagnose and treat thrombosis
on the basis of clinical signs and symptoms.
Clinical follow-up 
for CVC-related thrombosis
During admission, all patients were
examined routinely each day by attending
physicians for signs and symptoms sugges-
tive of CVC-related thrombosis including
pain, swelling, discoloration, the presence of
collaterals or CVC dysfunction. Discharged
patients were seen at the outpatient clinic
weekly by attending physicians. Clinical fol-
low-up took place until six weeks after CVC
removal.
Patients with clinically suspected throm-
bosis were referred to the department of
Radiology for ultrasound and, if indicated,
additional venography. Primary endpoint was
the number of clinically suspected CVC-
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Ultrasound criteria 
for CVC-related thrombosis
The criteria used for diagnosis of both
types of CVC-related thrombosis, subclinical
and clinically manifest, were similar. A diag-
nosis of CVC-related thrombosis by ultra-
sound was made according to predefined 
criteria. For veins accessible to direct insona-
tion, the criteria of non-compressibility, visu-
alisation of echogenic intravascular mass and
absence of respiratory variation (jugular, axil-
lary or subclavian vein) were used.10-14 For
veins inaccessible to direct insonation (mid-
dle part of the subclavian vein, brachio-
cephalic vein and superior caval vein) the cri-
terion of monophasic flow to detect
occlusive thrombosis was used.15
Venographic criteria 
for CVC-related thrombosis
Contrast venography, using a standard-
ised protocol, was used in patients with clini-
cally suspected thrombosis in whom ultra-
sound findings were apparently normal or
inconclusive. A diagnosis of thrombosis was
made in case of presence of an intraluminal
filling defect of a venous segment (axillary,
subclavian, brachiocephalic and superior
caval vein) or persistent non-filling of a
venous segment in the presence of collateral
circulation.16
Statistical analysis
Cumulative incidences for thrombosis
were analysed through Kaplan-Meier time to
event analysis. Endpoints were “subclinical
thrombosis” and “clinically manifest throm-
bosis” respectively. Patients were censored if
they died or reached the end of follow-up;
i.e. CVC removal for follow-up with ultra-
sound for subclinical thrombosis and six
weeks after CVC removal for clinical follow-
up for clinically manifest thrombosis.
Diagnostic accuracy indices for ultra-
sound to predict clinically manifest thrombo-
sis with 95% confidence intervals (CI95%)
were calculated: i.e. sensitivity, specificity,
positive predictive and negative predictive
values. Confidence intervals were based on
standard errors for binomial distributions




A total of 136 consecutive patients were
eligible for this study during the 18-month
study period. Informed consent was not
obtained in 26 eligible patients and two
patients were excluded because they met
exclusion criteria. Overall, 108 patients were
enrolled on the study protocol. Three
patients were excluded from the analysis: in
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two patients it was impossible to perform
ultrasound at CVC removal due to early hos-
pital discharge and one patient withdrew
informed consent after the start of the study.
Ultimately, complete data were obtained for
105 patients. The main characteristics of the
105 patients and the types of CVCs used are
shown in Table 1. The average age of the
patients was 48 years (range 16-77). The
average time of the CVC being in place was
21.7 days (range 5-64 days).
Subclinical thrombosis 
In 105 patients, 422 scheduled ultrasound
recordings were performed. At evaluation 20
(4.7%) were not interpretable. From the
remaining 402 recordings, 377 were of good
quality (89.3%) and 25 were of poor (5.9%),
but interpretable, quality. In 380 of 402 inter-
pretable recordings (94.5%) there was agree-
ment between the two observers (κ = 0.82).
The cumulative incidence of subclinical
thrombosis was 24.8% (26 of 105 patients)
(CI95%; 16.5% - 33%). The time from CVC
insertion to subclinical thrombosis is shown
in Figure 1. The 26 events of subclinical
thrombosis took place in a total of 2096 days
of follow-up (incidence 12.4/1000 days
(CI95%; 6.2/1000 to 21/1000 days). In 9 
of 26 events (34.6%), subclinical thrombosis
was observed within the first week after CVC
insertion. The remaining 17 events (65.4%)
were observed later during follow-up.
None of the patients with subclinical
thrombosis on the ultrasound screen under-
went initiation of anticoagulant treatment or
CVC removal, as the attending physicians










Acute myeloid leukaemia 46 (44)
Acute lymphoblastic leukaemia 13 (12)
Chronic myeloid leukaemia 11 (10)
Multiple myeloma 11 (10)
Non-Hodgkin lymphoma 9 (9)
Other 15 (14)
Therapy
Intensive chemotherapy 48 (46)
Stem cell transplantation (Allogeneic) 36 (34)
Stem cell transplantation (Autologous) 21 (20)
Central venous catheter
Double lumen 44 (42)
Triple lumen 56 (53)
Other 5 (5)
Insertion-site central venous catheter
Jugular vein 11 (10)
Subclavian vein 94 (90)
Anticoagulant treatment
None 92 (88)
Prophylactic dose (VOD*) 12 (11)
Therapeutic dose (atrial fibrillation) 1 (1)
* VOD = veno-occlusive disease of the liver
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Clinically manifest thrombosis
The cumulative incidence of clinically
manifest thrombosis in our patients was
12.4% (13 of 105 patients) (CI95% 6.1% -
18.7%). In another 12 patients (11.4%)
thrombosis was clinically suspected, but
excluded by diagnostic imaging. Most
patients with thrombosis had multiple 
signs or symptoms, including pain (n=12),
oedema (n=7), discoloration (n=6) or super-
ficial collateral circulation (n=4). The time
from CVC insertion to clinically manifest
thrombosis is shown in Figure 2. The 13
events of clinical manifest thrombosis took
place in 5901 days of clinical follow-up (inci-
dence 2.2/1000; CI95% 0.2/1000 - 7.2/1000
days). The median number of days between
insertion of the CVC and time of diagnosis
was 17 days (range 9-54 days). In 10 of the
13 patients (76.9%) thrombosis was diag-
nosed within the second and third week after
CVC insertion.
Interestingly, in five of the 13 patients
(38.5%) the episode of clinically manifest
thrombosis occurred after removal of the
CVC (range 3 - 40 days). All events were dia-
gnosed upon clinical suspicion by the attend-
ing physician and subsequently confirmed by
ultrasound or additional venography.
In all patients who still had a CVC at the
time of diagnosis of thrombosis, the CVC
was removed. All patients with clinically
manifest thrombosis received initially unfrac-
tionated heparin intravenously or a low
molecular weight heparin (LMWH) subcuta-
neously, followed by oral anticoagulant treat-
ment for a period of six weeks. During anti-
coagulant treatment, plateletcounts were
monitored and maintained at a level above 30
x109/L.
Diagnostic value of
screening ultrasound (Table 2) 
Of 13 patients with clinically manifest
thrombosis, there were nine in whom sub-
clinical thrombosis was identified earlier by
screening ultrasound (sensitivity 69.2%,
CI95%; 44.1% to 94.3%), whereas in the 92
patients without clinically manifest thrombo-
sis, 75 patients had persistent normal screen-
ing ultrasound tests and 17 had abnormal
ultrasound findings (specificity 81.5%;
CI95% 73.6% - 89.4%).
Of 26 patients with subclinical thrombo-
sis, nine developed clinically manifest throm-
bosis later during follow-up (positive predic-
tive value 34.6%; CI95% 16.3% - 52.9%).
The clinical diagnosis was made within a
week after the diagnosis of subclinical
thrombosis in eight patients. In the other
patient the interval between subclinical and
clinically manifest thrombosis was longer (6
weeks). However, in this patient an occluded
CVC led to extravasation of infusate, fol-
lowed by pain and swelling of the shoulder
which may have mimicked the signs and
symptoms of thrombosis as seen on screen-
ing ultrasound the day after CVC withdrawal.
In 79 patients in whom the ultrasound
screen remained normal throughout clinical
follow-up, four patients developed clinically
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manifest thrombosis (negative predictive
value 94.9%; CI95% 90.1% - 99.8%). In
three of these patients ultrasound remained
normal until signs and symptoms of mani-
fest thrombosis became apparent, and clini-
cally manifest thrombosis could only be
demonstrated in another patient by addition-
al venography.
From the 17 patients (16.2%) with sub-
clinical thrombosis only, nine in whom sub-
clinical thrombosis was diagnosed by sched-
uled screening ultrasound within 48 hours
from CVC removal. In the other eight
patients the CVC remained in place for at
least three more days. As CVC removal could
have had effect on the outcome of clinically
manifest thrombosis, we performed an analy-
sis with the classification “subclinical throm-
bosis” limited to patients with subclinical
thrombosis with prolonged catheterisation.
This increased the positive predictive value
to 52.9% (CI95% 29.3% - 76.7%), whereas
the negative predictive value was slightly
increased to 95.5% (CI95% 91.1% - 99.8%).
Discussion
Central venous catheter related thrombo-
sis is frequently observed in patients under-
going intensive chemotherapy or a stem cell
transplantation for haematological disease. In
this prospective cohort study we observed a
12% cumulative incidence of clinically mani-
fest thrombosis, which confirms previously
reported findings.4,5 In addition, we found
subclinical thrombosis in 16% of the
patients. Thrombosis therefore occurred in
over a quarter of our patients.
In this study, we show that screening
ultrasound in this population might be valu-
able for two reasons. Firstly, the presence of
subclinical thrombosis increased the risk of
72
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Figure 1. Time to event analysis for the group of
patients with subclinical central venous
catheter-related thrombosis
Figure 2. Time to event analysis for the group of
patients with clinically manifest throm-
bosis
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developing clinically manifest thrombosis to
35%. Secondly, in patients with normal
screening ultrasound findings the risk of
clinically manifest thrombosis was reduced
to 5%. Thus, the presence of subclinical
thrombosis, as seen on ultrasound, increased
the risk of clinically manifest thrombosis
sevenfold compared to negative ultrasound
findings (relative risk 6.8; CI95%; 2.3 - 20.3).
Anticoagulant prophylaxis might be 
useful, to reduce the rate of CVC-related
thrombosis. However, it should be noted 
that evidence-based data on anticoagulant
prophylaxis in haematology patients with
CVCs is very limited. In one study with 223
patients undergoing bone marrow transplan-
tation a reduction (from 13% to 5%) clinical-
ly manifest thrombosis was reported by
when 1 mg warfarin once daily was adminis-
tered.17 In this non-randomized study, a
group of historical controls (n=115) without
warfarin was used as a reference population.
In another retrospective study with 382
patients, two regimens of a short-term
course of prophylaxis using a LMWH were
given during the first 7-10 days after CVC
insertion.18 Both regimens, 7 days 2850 IE
(n=123) and 10 days 5700 IU of Nadroparin
(n=98), did not reduce the rate of clinically
manifest thrombosis (8%, respectively 7%)
as compared to a group of historical controls
(n=161) without Nadroparin (6%). In our
view, continued prophylaxis with a LMWH
over a prolonged period might be needed to
prevent the overall majority of events, as
thrombotic events in the study by Lagro et al.
mainly occurred after stopping Nadroparin-
prophylaxis (median 22 days).18 In our study,
three quarters of clinically manifest throm-
bosis occurred within the second and third
week after CVC placement. Interestingly,
clinically manifest thrombosis occurred at a
median-interval of 17 days after CVC place-
ment, a finding strikingly similar to the
observation by Lagro et al.18
The use of routine anticoagulant prophy-
laxis to prevent CVC-related thrombosis is,
however, still debated. It was shown that cli-
nicians are very reluctant to prescribe antico-
agulant prophylaxis routinely, because of a
low expected incidence of thrombosis and a
concern for bleeding complications in this
vulnerable population.7,8 Alternatively, identi-
fying patients at high-risk for thrombotic
complications may help haematologists to
individualise anticoagulant prophylaxis, i.e.
making decisions in which patient anticoagu-
lant prophylaxis might be warranted or not.5,8
In patients with persistent normal screening
ultrasound tests, which represent the overall
majority of our patients, our data suggest
that anticoagulant prophylaxis might be with-
held. Anticoagulant prophylaxis, (low dose)
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Table 2. The risk of clinically manifest and subclinical thrombo-




Subclinical thrombosis 9 17 26
No subclinical thrombosis 4 75 79
Total 13 92 105
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therapy or other interventions like timely
CVC removal could be restricted to high-risk
groups, e.g. such as our patients with subclin-
ical thrombosis on ultrasound. However, the
effects of these interventions in patients are
currently uncertain and further studies,
including individualised based anticoagulant
prophylaxis versus prolonged routine antico-
agulant prophylaxis, are needed to evaluate
which is the best strategy to prevent clinically
manifest thrombosis. Furthermore, our data
suggest that CVC removal upon diagnosis of
subclinical thrombosis could reduce the risk
of a manifest event; this observation clearly
needs prospective validation.
Implementation of our findings warrants
comment. Screening ultrasound performed
weekly is labour-intensive. It may be possible
to reduce the number of patients and exami-
nations performed by selecting patients at
high-risk for CVC-related thrombosis based
on clinical risk assessment prior to the inser-
tion of a CVC. Currently, reliable studies in
which common risk factors for venous
thrombosis that contribute to CVC-related
thrombosis are scarce.5 Interestingly, in one
study of patients with factor V Leiden who
underwent bone marrow transplantation, a
cumulative incidence of clinically manifest
thrombosis of 54% was reported.5 Clearly,
more studies are needed to identify common
acquired and genetic risk factors in venous
thrombosis to identify those patients in
whom screening with ultrasound might be
advantageous.
Venography is currently the reference
standard in the diagnosis of upper limb vein
thrombosis, however it is clearly not accept-
able as a screening procedure in this vulnera-
ble patient group. Ultrasound has the advan-
tage that it is non-invasive, gives no radiation
exposure, and can easily be performed serial-
ly at the patients’ bedside. The accuracy of
ultrasound is highly dependent on the criteria
used for detecting thrombosis. With the cri-
teria used for upper limb thrombosis with
ultrasound, a high specificity in literature has
been reported (92-100%).10-15 The reported
sensitivity ranges from 78 to 96%, which
means that our reported incidence of throm-
bosis could be an underestimation. In our
study, 5% of patients with clinically manifest
thrombosis had persistent normal screening
ultrasound examinations. Whether venogra-
phy would have identified these patients is
unknown, as it was not used routinely.
In addition, the accuracy of ultrasound is
likely to be operator dependent. In the pres-
ent study, all of the scans were performed 
by a single, experienced, ultrasonographer.
Although we observed a high interobserver
agreement in ultrasound evaluation, the accu-
racy of ultrasound is rather dependent on a
reliable real-time investigation, which is
enhanced by an experienced operator.
In conclusion, we observed a high inci-
dence of CVC-related thrombosis in patients
undergoing intensive chemotherapy or a
stem cell transplantation for haematological
disease. Screening with ultrasound in haema-
tology patients enabled discrimination
between a high- and a low-risk group for
clinically manifest thrombosis. Further stud-
ies are needed to identify those patients for
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whom screening would be advantageous and
what preventative strategy, including risk-cal-
culation based individualised anticoagulant
prophylaxis, timely CVC removal, and pro-
longed routine anticoagulant prophylaxis is
most likely to safely prevent clinically mani-
fest thrombosis.
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Abstract
Purpose. We studied whether the risk of central venous catheter-related thrombosis
increased after an episode of catheter-related infection in haematology patients undergoing
intensive chemotherapy. Secondly, we determined whether thrombosis can be predicted or
excluded by catheter lock fluid surveillance cultures.
Patients and Methods. In a prospective setting, 105 consecutive patients were carefully
examined for central venous catheter-related infection and thrombosis. In all patients micro-
bial surveillance cultures of catheter lock fluid were taken every other day. All patients with
clinical suspicion of central venous catheter-related thrombosis underwent ultrasound, or
additional venography.
Results. The cumulative incidence of central venous catheter-related infection was 24%
(25 of 105 patients). Clinically manifest thrombosis occurred in 13 (12%) of 105 patients. In
patients with central venous catheter-related infection, the risk of thrombosis increased
markedly in comparison to those without infection (relative risk 17.6; CI95% 4.1 - 74.1). In
patients having two or more positive subsequent catheter lock fluid cultures with identical
micro-organisms, 71.4% developed thrombosis, as compared to 3.3% in patients with negative
or a single positive culture.
Conclusions. The risk of clinically manifest thrombosis is increased after an episode of
central venous catheter-related infection in haematology patients. Surveillance culturing of
catheter lock fluid may be clinically useful in estimating the risk for thrombosis and the insti-
gation of focused early intervention.
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Introduction
In patients who undergo intensive
chemotherapy or a stem cell transplantation,
central venous access is often needed. The
use of a central venous catheter (CVC) may
be complicated by thrombosis and associated
complications such as pulmonary embolism,
which may lead to premature removal of the
CVC and anticoagulant treatment.1,2 These
patients, who often suffer from thrombocy-
topenia, are particularly vulnerable for bleed-
ing complications.
An association of CVC-related infection
with CVC-related thrombosis has been sug-
gested previously.3-5 However, the reported
thrombotic events were subclinical and often
diagnosed at CVC removal. Whether CVC-
related infection increases the risk of clinical-
ly manifest thrombosis while the CVC
remains in place is unknown. It is highly rele-
vant to investigate this association, since
early determination and intervention upon
the diagnosis of infection in these patients
could lead to CVC salvage and may prevent 
thrombotic complications. We undertook a
prospective study to evaluate whether, and
to what extent, CVC-related infection
increases the risk of subsequent clinically
manifest thrombosis. In addition, we
assessed the predictive value of surveillance
CVC lock cultures in the diagnosis of throm-
bosis, which gives information on the poten-
tial benefits of prevention of thrombotic
complications.
Patients and Methods
Patients and study design
This study was performed at the depart-
ment of Haematology of the Leiden
University Medical Center (LUMC) from
October 2000 until May 2002, a tertiary
referral center for haematological disease in
the Netherlands.6 The study protocol was
approved by the local medical ethical com-
mittee, and all participating patients gave
written informed consent. All consecutive
patients 16 years or older with a CVC insert-
ed for over 48 hours were considered for
enrollment.
CVCs were inserted via the subclavian or
jugular vein and used for administering cyto-
toxic drugs and supporting treatment (i.e.,
fluids, blood products, parenteral feeding
and antimicrobial therapy). Nurses were
allowed to withdraw blood from the CVC
for diagnostic purposes and monitoring. The
lumina of the CVC were rinsed daily with
urokinase (3750 IU in 1.5 ml sodium chlo-
ride). The use of urokinase for the preven-
tion of CVC-related complications was
based on local experience (not yet pub-
lished), as well as other studies, the data of
which suggest that urokinase may reduce the
risk of (serious) infectious CVC complica-
tion as compared to heparin and saline
alone.7,8 No antibiotic prophylaxis specifically
for CVC-related infections were given. All
patients were treated according to a local
protocol to prevent infections with aerobic
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Gram negative rods, viridans streptococci and
Candida spp.9 Prophylactic treatment included
neomycin (250 mg), polymyxin B (1.106 IU)
orally q.d., pipemidic acid 400 mg orally
b.i.d., amphotericin B 200/10mg q.d.. After
10 days of treatment, the dosage of the
regime was reduced (half of the dosage in
mg), except for the pipemidic acid.
Patients with abnormal ultrasound find-
ings (performed within 48 hours after inser-
tion) were excluded if they had a previous
CVC at the same insertion-site, or if they
had a proven thrombosis at the same inser-
tion-side. Patients who were unable to under-
go ultrasound were also excluded.
Microbiological
surveillance and treatment 
Starting the day after the insertion of the
CVC, lock fluid was cultured routinely each
second day as described previously.10 If a sur-
veillance CVC lock fluid culture yielded
growth of micro-organisms (positive lock
culture), lock cultures were drawn daily. At
each episode of onset of fever (body tem-
perature >38.5 °C) or other symptoms or
signs of infection (hypotension, chills,
hypothermia, unexplained tachycardia) blood
cultures were drawn, at least one via the CVC
and one by standard venipuncture. At least
two blood cultures were drawn on each con-
secutive day in all patients with clinical symp-
toms or signs of infection, until a causative
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Table I. Definitions of the different types of CVC-related infection adapted to earlier studies
Descriptions
1. Local CVC-related infection
a). Insertion-site infection. The CVC insertion-site exhibits clinical signs of inflammation with the swab Gram stain > 20 micro-organisms per
field of vision (1000x) and a positive culture within 48 hours. The CVC lock fluid and blood cultures remain negative.
b). Significant CVC colonization. At least two consecutive CVC lock cultures become positive within 48 hours or the CVC tip culture is 
positive. Blood cultures by venipunture are negative; CVC drawn blood cultures may yield identical micro-organisms.
2. Systemic CVC-related infection
CVC-related bacteraemia. Presence of fever (body temperature > 38.5 °C) or clinical signs or symptoms of infection, and blood cultures are 
positive. The insertion-site swab, CVC tip culture or a positive CVC lock culture yields growth of identical micro-organisms. A systemic CVC-
related infection with positive blood cultures* at least 24 hours after adequate antimicrobial therapy is considered as a major systemic CVC-relat-
ed infection.
* In case of coagulase-negative staphylococci, at least two drawn bloodcultures are positive.
CVC = central venous catheter
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micro-organism was isolated. In the presence
of clinical signs of inflammation at the inser-
tion site (i.e. erythema, exudation, tender-
ness, warmth or swelling) swab cultures were
taken. Catheter tip cultures were not per-
formed routinely, only to support the diag-
nosis of CVC-related infection. Micro-
organisms were identified by current tests
(DNAse testing), additional commercial ID
32 STAPH biochemical test strips (API,
bioMerieux®) and anti-microbial sensitivity
patterns.
The criteria for establishing a diagnosis
of CVC-related infection were adapted to
previous studies.10,11 Two entities were distin-
guished: “local CVC-related infection” and
“systemic CVC-related infection” (Table 1).11
In case of a proven insertion-site infection
or CVC colonization, appropriate antimicro-
bial therapy was started. The CVC was left in
place. If a single CVC lock fluid culture was
positive, no treatment was started. In case of
fever or other symptoms or signs of systemic
infection empirical therapy was started (cef-
tazidime 500 mg intravenously t.i.d. and
teicoplanin 200 mg intravenously b.i.d. on
day one, q.d. on consecutive days). Empirical
therapy was discontinued if blood cultures
remained negative after 72 hours. If a sys-
temic CVC-related septicemia was diagnosed,
empirical therapy was adjusted to the most
appropriate small-spectrum regimen.7 The
CVCs were not removed routinely.
Outcome: CVC-related thrombosis
During admission, all patients were rou-
tinely examined each day for symptoms and
signs of CVC-related thrombosis; pain,
swelling, discoloration, visible collateral cir-
culation or CVC dysfunction. Discharged
patients were seen once weekly at the outpa-
tient clinic by attending physicians. Patients
with a clinical suspicion of CVC-related
thrombosis were referred to the department
of Radiology for ultrasound. If ultrasound
findings appeared normal or were inconclu-
sive, additional venography was performed.
In addition, for this study, all patients with
clinically suspected thrombosis were exam-
ined by an independent examiner who per-
formed ultrasound. These examinations were
coded and assessed by a panel of two blind-
ed physicians experienced in ultrasound eval-
uation. If needed, a third expert opinion was
asked. A diagnosis of thrombosis was made
when ultrasound recordings were abnormal,
or when normal or inconclusive, by an
abnormal venogram. Follow-up for CVC-
related thrombosis took place until 6 weeks
after CVC removal.
A diagnosis of CVC-related thrombosis
was made according to predefined criteria.
For veins accessible to insonation, the crite-
ria of non-compressibility, visualization of
echogenic intraluminal mass and absence of
respiratory variation (jugular, axillary or sub-
clavian vein) were used.12-15 For veins inacces-
sible to direct insonation (middle part of the
subclavian vein, brachiocephalic vein and
superior caval vein), the criterion of
83
Catheter-Related Infection and Thrombosis
boek_inhoud.qxp  23-11-2005  21:09  Pagina 83
monophasic flow to detect occlusive throm-
bosis was used.16 A diagnosis of thrombosis
by contrast venogram was made in case of
intraluminal filling defects of a venous seg-
ment (axillary, subclavian, brachiocephalic or
superior caval vein) or persistent non-filling
of a venous segment in the presence of col-
lateral circulation.17
Statistical analysis
Cumulative incidences for infection and
thrombosis were calculated as number of
first events over the number of individuals at
baseline and Kaplan-Meier statistics were
performed. Patients were censored if they
died or reached the end of follow-up.
Relative risks (RR) and 95% confidence
intervals (CI95%) were calculated and based
on standard errors for binominal distribu-
tions. The relation of infection and throm-
bosis was assessed by applying Fisher’s exact




The main patient and CVC characteristics
have been described in detail elsewhere.6
Briefly, from 136 consecutive patients, 110
consented to participate. Two patients were
excluded before the start of the study and
three patients were excluded from the analy-
sis based on exclusion criteria. Ultimately, for
105 patients complete data were obtained
and evaluated. The main characteristics for
these 105 patients are shown in Table 2.
None of the pre-treatment parameters in
Table 2 predisposed for CVC-related infec-
tion or thrombosis.
In 25 patients CVC-related thrombosis
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Table II. Baseline characteristics of the study patients
Mean (range)
Age (years) 48 (16 – 77)






Acute Myeloid Leukaemia 46 (43.8)
Acute Lymphoblastic Leukaemia 13 (12.4)
Lymphoma 13 (12.4)
Chronic Myeloid Leukaemia 11 (10.5)
Multiple Myeloma 11 (10.5)
Other 11 (10.5)
Therapy
Intensive Chemotherapy 48 (45.7)




Double or Triple lumen 100 (95.2)
Subclavian vein 94 (89.5)
Left insertion-side 71 (67.7)
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was clinically suspected upon symptoms and
signs. In 13 out of these 25 patients clinically
manifest thrombosis was objectified (cumu-
lative incidence 12.4%; CI95% 6.1% -18.7%).
In the other 12 patients thrombosis was
excluded by diagnostic imaging. There was
no disagreement between the real time diag-
nosis and the diagnosis as judged by our
blinded panel.
CVC-related infection and risk 
of clinically manifest thrombosis 
The cumulative incidences for CVC-relat-
ed infections and the absolute and relative
risks of subsequent clinically manifest
thrombosis are summarized in Table 3.
Overall, CVC-related infection was observed
in 25 of 105 patients (cumulative incidence
23.8%; CI95% 15.7% - 32%). In 11 patients
(10.5%) CVC-related infection was classified
as a local CVC infection, i.e. CVC coloniza-
tion (n=1), a local insertion-site infection
(n=6) or both (n=4) in the absence of asso-
ciated bacteraemia. Swab and CVC lock-fluid
cultures yielded mainly coagulase-negative staphy-
lococci (CoNS; n=6) or multiple types of
micro-organisms including CoNS (n=3).
Other isolated pathogens were Enterobacter
spp. (n=1) and Acinetobacter spp. (n=1).
Another 14 patients (13.3%; CI95% 6.8% -
19.8%) suffered from systemic CVC-related
infection. In these patients blood cultures
yielded CoNS (n=10), multiple types of
micro-organisms including CoNS (n=3), and
Corynebacterium spp. (n=1).
In the group of patients with a CVC-
related infection the frequency of subse-
quent clinically manifest thrombosis was
44% (11 of 25 patients), compared with 3%
thrombosis in the patients without CVC-
related infection (two of 80 patients; p <
0.05). This yields a relative risk of 17.6
(CI95% 4.1 - 74.1). Our findings suggest that
the absolute risk of clinically manifest
thrombosis increases with the severity of
infection, since thrombosis was observed in
57.1% of patients with systemic CVC-related
infection as compared to 27.3% in patients
with a local CVC infection (Table 3).
The frequency of CVC-related infection
in the group of patients with objectified
CVC-related thrombosis was higher than in
the group of patients in whom thrombosis
was clinically suspected but ruled out (84.6%
vs. 16.7%), indicating that the observed asso-
ciation of infection with thrombosis was not
affected by the knowledge of infection
among attending physicians who had decided
on referral for diagnostic imaging for throm-
bosis.
Fifteen patients had a systemic infection
(14.3%; CI95% 7.6% - 21%) classified as
unrelated to the CVC. Blood cultures 
in these patients yielded CoNS (n=4),
Streptococcus spp. (n=3), multiple types of
micro-organisms (n=3), Candida albicans
(n=2) or other micro-organisms (n=3). From
these patients only one suffered from clini-
cally manifest thrombosis (6.7%).
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Accuracy for CVC lock 
fluid cultures to predict 
clinically manifest thrombosis 
During follow-up, 30 of 105 patients had
at least one positive surveillance CVC lock
culture (28.6%). Of 13 patients with clinical-
ly manifest thrombosis, 11 had at least one
prior positive culture (sensitivity 84.6%;
CI95% 65% - 100%). In 73 of 92 patients
without clinically manifest thrombosis, a neg-
ative culture was obtained for a specificity of
79.3%; CI95% 71.1% - 87.6%). In 75
patients with serially negative CVC lock fluid
cultures, thrombosis occurred in 2 patients
(negative predictive value 97.3%; CI95% 93.7
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Table III. Observed cumulative incidences of central venous catheter-related infections and the absolute and relative risks of subsequent clinically
manifest thrombosis.
Number (%) Risk of thrombosis *
No CVC-related infection 80 (76.2) 2.5%
CVC-related infection‡
1. Local CVC-related infection 11 (10.5) 27.3% (10.9)
Insertion-site 6
CVC colonization 1
Insertion-site and CVC colonization 4
2. Systemic CVC-related infection 14 (13.3) 57.1% (10.4)
Overall 25 (23.8) 44.1% (17.6)
* Absolute risks of thrombosis in percentages, between braces the relative risks.
‡ For definitions of CVC-related infection, see Table 1.
CVC = central venous catheter
Figure 1. The risk of clinically manifest throm-
bosis based on at least two surveillance
central venous catheter lock fluid cul-
tures.
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% - 100%), whereas 11 out of 30 patients
with a positive CVC lock fluid developed
thrombosis (positive predictive value 36.7%;
CI95% 19.4% - 53.9%). If two or more sub-
sequent positive cultures with identical
strains of micro-organisms were used to pre-
dict symptomatic thrombosis the positive
predictive value increased to 71.4%, whereas
the negative predictive value decreased only
slightly (96.7%). As illustrated in Figure 1,
the risk of thrombosis increased markedly in
patients with two or more consecutive posi-
tive cultures, compared with only one posi-
tive followed by negative cultures or consec-
utive negative cultures.
The time interval between the first posi-
tive surveillance culture and the clinical diag-
nosis in 11 patients with clinically manifest
thrombosis ranged from 1 to 39 days (mean
9 days).
Discussion
In the present study, we show a clear
temporal association of CVC-related infec-
tion and thrombosis. After an episode of
CVC-related infection the risk of clinically
manifest thrombosis increased markedly (RR
17.6). Besides, our findings suggest that the
absolute risk of developing a symptomatic
thrombotic event increases with the severity
of CVC-related infection; a 57% thrombosis
risk was observed after an episode of CVC
associated septicemia, versus 27% in patients
with a local CVC infection.
Previously, a direct association of CVC-
related infection and thrombosis has been
suggested in autopsy studies.3 Reliable
prospective data in which a direct relation-
ship of CVC-related infection and thrombo-
sis has been reported are scarce.4,5 In a study
of critically ill patients (n=208), the presence
of subclinical thrombosis detected by rou-
tine ultrasound performed at CVC removal
was associated with a three-fold increased
rate of systemic CVC-related septicemia.4 In
haemato-oncology patients only one small
study (n=42) has been performed, in which a
direct association of infection and thrombo-
sis was reported.5 In this study, daily screen-
ing using ultrasound for (subclinical) throm-
bosis was used to estimate the risk of
subsequent CVC-related infection. From 13
patients with documented subclinical throm-
bosis, CVC-related infection occurred in 12
(92%), whereas in 29 patients without
thrombosis, the number of infections was
only two (7%).5 The main difference between
our and these studies is that we have used
clinically manifest thrombosis as the primary
endpoint and that CVC-related infection was
used as a parameter to predict symptomatic
thrombotic events.
Based on our findings, as well as results
from earlier studies, it could be argued that
the relationship of thrombosis and infection
is bi-directional. Thrombus formation, which
is commonly observed after catheterization,
may play an important role in the develop-
ment of certain CVC related infections.4,5,18,19
The composition of CVC-associated throm-
bi consists of several proteins such as fibrin,
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fibronectin, collagen, laminin and several
types of immunoglobulins.20-22 Micro-organ-
isms, especially Staphylococcus aureus and cer-
tain types of CoNS, easily adhere to throm-
bin sheaths, which could explain the clinical
observation of a close association of CVC-
related infection and thrombosis.20-23 Besides,
CVC-related infection might induce an
inflammatory response,24 that could induce
or lead to further progression of excessive
thrombus formation. Thrombosis and infec-
tion might also just be two separate entities
occurring simultaneously in patients being
severely ill, but this hypothesis is not likely,
since the molecular basis of thrombosis sug-
gests a direct relationship.20-24 We can not,
however, exclude that thrombosis may be
induced by a local chemical phlebitis caused
by antibiotics in patients treated for CVC-
related infection.
From a clinical point of view, surveillance
cultures of CVC lock fluid may be valuable
to assess the risk of clinically manifest
thrombosis in individual patients, particularly
if this risk assessment is based on serially
determined cultures. Such a strategy could
allow early intervention in addition to ade-
quate antimicrobial therapy. Timely CVC
removal at the first sign of thrombosis or
infection, or individualized anticoagulant
prophylaxis, may be beneficial. Such individ-
ualized risk assessment for clinically manifest
thrombosis might be an alternative for rou-
tine anticoagulant prophylaxis in haematol-
ogy patients with CVCs, especially after
intensive chemotherapy.25 However, this
study was an observational study, and
whether early intervention would have
changed clinical outcome and whether this
such a strategy is cost-effective is unknown
and should be investigated. Although antico-
agulant prophylaxis is recommended in con-
sensus guidelines, there is great reluctance
amongst clinicians to prescribe anticoagulant
prophylaxis routinely because of fear of
bleeding complications and a low expected
incidence of thrombosis.25-27 In addition,
since the seems to be a strong association of
infection and thrombosis, the use of antibi-
otic impregnated CVCs may be of clinical
benefit as well. However, the outcome of
intervention(s) based on surveillance cultures
is currently unknown and this clearly needs
prospective evaluation before routinely
implemented. Whether such intervention is
based on a single or multiple subsequent
positive lock cultures is uncertain. However,
as in CVC-related infection, the accuracy-
indices of surveillance cultures to predict
clinically manifest thrombosis improved with
more subsequent cultures (two or more) that
were positive for identical types and strains
of micro-organisms. Serially positive cultures
are likely to reflect a more significant colo-
nization of the CVC, or less frequently, con-
tamination as compared with a single positive
surveillance culture.
In conclusion, we have shown a close
association of CVC-related infection with
thrombosis. The risk of developing clinically
manifest thrombosis increases substantially
after an episode of CVC-related infection
(RR 17.6) and is enhanced by the severity of
the infection. Routine culturing of CVC lock
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fluid is clinically useful to monitor the risk of
clinically manifest thrombosis, which might
allow early intervention. However, the out-
come of such a strategy is currently
unknown and clearly needs to be explored
prospectively.
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Abstract
Introduction. Patients with a central venous catheter who are treated with chemotherapy
for haematological or solid tumour malignancies have a high risk of developing thrombosis.
There is consensus on anticoagulant prophylaxis in cancer patients with a central venous
catheter, but incidental findings suggested a poor physician compliance.
Materials and Methods. We performed a large survey of medical departments of Dutch
hospitals (General Internal Medicine, Haematology and Oncology) to assess the policy of
physicians in prescribing anticoagulant prophylaxis for central venous catheter-related throm-
bosis in patients with haematological or solid tumour malignancies.
Results. Central venous catheters were used in most medical departments of Dutch hos-
pitals (Haematology 84%, Oncology 85%). A minority of the physicians responded to pre-
scribe anticoagulant prophylaxis routinely (10% Haematology, 21% Oncology) according to
the American College of Chest Physicians or national Dutch consensus. The most important
reasons for not prescribing prophylaxis were a low perceived risk of clinically manifest throm-
bosis and the fear of haemorrhage.
Conclusions. For most physicians the perceived increased risk of bleeding outweighs the
benefit of anticoagulant prophylaxis, i.e. reducing the rate of manifest thrombosis.
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Introduction
Thrombosis is a well-recognised compli-
cation of a central venous catheter (CVC),
especially in haematology and oncology
patients. In cancer patients an incidence-rate
of thrombosis of 42% has been reported.1
The thrombus may be a source for pul-
monary embolism and associated infection.2,3
Subsequent anticoagulant treatment of
thrombosis may be associated with haemor-
rhage in this vulnerable population and may
delay chemotherapy.
The use of anticoagulant prophylaxis for
CVC-related thrombosis has been studied
with unfractionated heparin (UFH), low
molecular weight heparin (LMWH) and low
dose warfarin.4-6 In the American College of
Chest Physicians (ACCP) consensus on anti-
coagulant prophylaxis it is suggested that
warfarin (1 mg daily) or LMWH should be
given to cancer patients with a CVC.7 The
Dutch consensus is in concordance with
this.8 Data on the implementation of these
consensus guidelines are limited. One report
from a single hospital in the United States
suggested that physicians are reluctant to
prescribe anticoagulant prophylaxis in cancer
patients with CVCs.9
The aim of this survey was to assess the
physician compliance with consensus guide-
lines at medical departments in the Nether-
lands where haematology and oncology
patients are treated with chemotherapy.
Materials and Methods
We conducted a survey of all hospital-
departments of General Internal Medicine,
Haematology or Oncology in the Nether-
lands. In April 2001, a postal questionnaire
was sent to a member of staff of the eligible
hospitals. A reminder was sent to all non-
respondents after 8 weeks.
The questionnaire contained three topics:
1) Use of CVCs for chemotherapy 
2) Systematic use of anticoagulant prophy-
laxis in patients with CVCs
3) Rationale for the absence of systematic
use of anticoagulants. Options given in
the questionnaire included:
a. A low expected rate of clinically manifest
thrombosis
b. A high perceived risk of bleeding
c. Preference of other regimes or policy
(UFH-locks or flushes)
d. No awareness of consensus-guidelines 
e. Other reasons
In addition, questions were asked about the
type of anticoagulant prophylaxis (UFH,
LMWH, coumarin derivatives) and the dose;
about the influence of platelet counts on this
treatment, as well as of the expected dura-
tion of the CVC.
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Results
We sent 157 questionnaires to medical,
Haematology and Oncology departments
involved in the treatment of cancer patients,
of which 116 were returned (response-rate
74%). The response was similar for depart-
ments where haematology (37 of 51) and
oncology patients were treated (79 of 106
questionnaires). In most departments CVCs
were used to administer chemotherapy and
supporting treatment for haematology (84%)
and oncology patients (85%). The results of
the questionnaire are summarised in Figure 1.
Overall, in three of 31 (10%) of
Haematology and in 14 of 67 (21%) of the
Oncology departments , prescription of anti-
coagulant prophylaxis for CVC-related
thrombosis was routine policy. The most fre-
quently used type of anticoagulant prophy-
laxis was a LMWH (88%), at a low dose of
2850 anti-Xa units, although in some centres
a therapeutic dose (up to 7500 anti-Xa units)
was given. Low-dose coumarin derivatives (1
mg acenocoumarol once daily) were used at
two departments where anticoagulant pro-
phylaxis was prescribed as a standard policy.
The platelet count was an important
parameter in the decision on prescribing pro-
phylaxis. In nine clinics (53%) where antico-
agulant prophylaxis was used, prophylaxis
was not given if the platelet count dropped
below 50x109/L. The expected duration of
stay of the catheter was not a major factor; in
only two (12%) of the departments, antico-
agulant prophylaxis was not started when the
expected duration of stay of the CVC was
less than 14 days.
The two most important reasons given
for not having a routine policy of anticoagu-
lant prophylaxis were a low expected inci-
dence of clinically manifest thrombosis or
the fear for haemorrhage (62%). This was
also reflected by the preference for heparin
locks or flushes (38%), which some respon-
dents considered to give less systemic antico-
agulant effects. Several physicians mentioned
spontaneously that they did not feel the con-
sensus guidelines to be sufficiently convinc-
ing to prescribe anticoagulant prophylaxis
(29%). Only a minority of contacted physi-
cians responded not to be familiar with the




Figure 1. The policy of prescribing anticoagulant
prophylaxis (no prophylaxis, LMWH or
low dose coumarin) for central venous
catheter related-thrombosis amongst
centres involved in treatment of oncol-
ogy and haematology patients.
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Discussion
This survey reveals that in a minority of
the Dutch clinics where chemotherapy is
given, anticoagulant prophylaxis for CVC-
related thrombosis is prescribed according to
national and international guidelines, in spite
of general awareness of consensus guide-
lines. In the ACCP consensus, it is suggested
that 1 mg warfarin daily or LMWH can be
administered in cancer patients with a CVC.7
This advice is based on two randomised tri-
als. In the first trial there was a reduction
from 38% to 10% of venogram documented
thrombosis in patients with malignancies by
1 mg Warfarin daily.4 In the second trial a
reduction from 62% to 6% of venogram
documented thrombosis was observed by
administering Dalteparin 2500 IU subcuta-
neously once daily.5 
The low compliance among physicians to
prescribe anticoagulant prophylaxis in this
large survey is similar to an incidental find-
ing.9 In the tudy by Carr and Rabinowitz, an
initial 10% compliance was observed, which
increased to only 20% after notification of
the physicians about the policy and benefits
of anticoagulant prophylaxis.9 However, rea-
sons for a poor compliance remained unclear
from this study. In our survey, the most
important reasons given for not prescribing
anticoagulant prophylaxis were the fear for
bleeding under anticoagulant prophylaxis and
a low expected incidence of clinically mani-
fest thrombosis.
According to our survey, the presumed
increased risk of bleeding in patients treated
with chemotherapy depended largely on the
occurrence of thrombocytopenia, which is
commonly observed in patients undergoing
chemotherapy. Available data from ran-
domised trials concerning the safety of anti-
coagulant prophylaxis are mainly restricted
to patients with normal baseline or only
slightly decreased platelet counts (over
100x109/L).4,5 In our view, the contribution
of anticoagulant prophylaxis to an increased
risk of bleeding cannot be extrapolated to
groups of patients with lower platelet counts.
The incidence of clinically manifest
thrombosis in the contacted clinics of our
survey is unknown. The observed incidence
of clinically manifest CVC-related thrombo-
sis varies widely between studies. The aver-
age overall incidence of clinically manifest
thrombosis in patients with solid tumour and
haematological malignancies from recently
performed studies was 6-12%.9-11 Selecting
patients with a high risk profile for develop-
ing manifest thrombosis might help clini-
cians to decide in whom anticoagulant pro-
phylaxis is warranted or not.10 For example,
in patients undergoing bone marrow trans-
plantation and carriers of factor V Leiden,
the incidence of clinically manifest thrombo-
sis may be as high as 54%.10
In conclusion, despite an evidence-based
recommendation of anticoagulant prophy-
laxis for CVC-related thrombosis, routine use
it is not generally implemented. We think
that this survey shows that more evidence is
needed to firmly establish the risk-benefit
ratio for broader implementation of consen-
sus guidelines.
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Summary
Venous thrombosis is a well-known com-
plication of central vein catheters (CVCs),
which may cause serious morbidity and may
result in potentially lethal complications such
as pulmonary embolism (PE). In this thesis
the general risk of CVC-related thrombosis
has been assessed, i.e., what is the overall risk
of developing CVC-related thrombosis?
Which patients are prone to develop throm-
bosis with its associated morbidity? Are we
able to predict this risk by routine surveil-
lance in patients? Better knowledge of the
incidence of CVC-related thrombosis and
identification of high-risk groups will assist
clinicians in decision making about CVC use
in the various patient groups and in whom
anticoagulant prophylaxis may be warranted.
The best moment to identify patients
with a high risk and those at lesser risk is
before CVC introduction. The incidence of
CVC-related thrombosis and the contribu-
tion of common inherited coagulation disor-
ders (Factor V Leiden (FVL), prothrombin
G20210A) to it, studied in a large hospital
population, were described in chapter 3.
Overall, the cumulative incidence of CVC-
related thrombosis (clinically silent and man-
ifest) in our patients was 30%. The presence
of heterozygous FVL or prothrombin
G20210A mutation increased the risk of
thrombosis nearly three-fold (relative risk
2.7; CI95% 1.9 - 3.8). In addition, a personal
history of venous thrombosis was positively
associated with CVC-related thrombosis.
Clinically manifest thrombosis was observed
in 7% of our patients. Clinically manifest
thrombosis clearly occurred more often in
the absence of anticoagulants and in patients
who received intensive chemotherapy.
The characteristics of patients with per-
manent pacemaker leads differ from patients
with CVCs used for infusion. Many patients
receive anticoagulant treatment at a high
(therapeutic) intension , the leads are perma-
nent in situ (lifelong), and there is a closed
device-system (less manipulation and risk of
infection). Risk assessment of a group of
145 patients who underwent pacemaker-
implantation is described in chapter 4.
Although thrombosis was observed 
in 23% of patients, most events did not
cause signs or symptoms (clinically manifest
thrombosis 1.5%). Thrombosis was
observed mostly within the first three
months after lead-implantation. The absence
of anticoagulant therapy increased the risk of
thrombosis substantially. Analogous to what
we observed in patients with a CVC, estab-
lished risk factors in venous thrombosis (use
of hormone therapy and a personal history
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of venous thrombosis) were associated with
an increased risk of thrombosis in patients
with pacemaker leads. In addition, the risk of
thrombosis increased in the presence of mul-
tiple pacemaker leads as compared to one
single lead.
Obviously, clinically manifest CVC-relat-
ed thrombosis may result in severe morbidity
or associated complications such as PE or
infection. In clinical practice it may be
worthwhile to screen certain high-risk
patients by frequent monitoring. Patients
who received intensive chemotherapy or
stem cell transplantation for haematological
disease had a substantial risk of manifest
thrombosis (13%). Both serially performed
ultrasound (Chapter 5) and surveillance
CVC lock cultures (Chapter 6) were evaluat-
ed as predictors of clinically manifest throm-
bosis. Both techniques were shown to be
clinically useful in predicting or excluding
manifest thrombosis in those high-risk
patients.
In chapter 5 we evaluated whether
screening with ultrasound for subclinical
thrombosis could predict clinically manifest
thrombosis later in follow-up. In this study, a
positive ultrasound screening test for sub-
clinical thrombosis increased the relative risk
of developing subsequent clinically manifest
thrombosis substantially (positive predictive
value 34%; negative predictive value 5%; rel-
ative risk 6.7).
In chapter 6, we show the clear relation
of CVC-related infection and -thrombosis.
When routine surveillance cultures of CVC
lock fluid are performed (cultures drawn
each second day), the risk of clinically mani-
fest thrombosis, in the presence of a single
positive culture, was 33%. This predictive
value increased to 71 % in patients with two
or more positive subsequent CVC lock fluid
cultures with identical microorganisms.
As outlined in Chapter 7, implementa-
tion of anticoagulant prophylaxis for CVC-
related thrombosis is still under debate, espe-
cially in (haemato-)oncology patients. In a
national survey, we investigated the compli-
ance rate of prescribing anticoagulant pro-
phylaxis amongst oncology (n=67) and
haematology departments (n=31) where
patients with a CVC were treated with
chemotherapy. Prescription of anticoagu-
lants was used to prevent CVC-related
thrombosis in only 10% (Haematology
departments), to 21% (Oncology depart-
ments) of the Dutch medical departments.
Important reasons for not complying with
consensus guidelines were a low expected
incidence of CVC-related thrombosis, and a
presumed high risk of bleeding in these
patients.
In conclusion, in view of physicians’
reluctance of prescribing prophylactic anti-
coagulant treatment in vulnerable patients,
the a priori determination of common inher-
ited and acquired risk factors may form a
basis to guide (prophylactic) treatment deci-
sions. Vulnerable patients may benefit the
most, i.e. those who have a high risk of clini-
cally manifest thrombosis, and who are at
risk of haemorrhage, such as patients who
undergo intensive chemotherapy. Besides,
surveillance of these patients with screening
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by ultrasound, or alternatively surveillances
cultures, may be useful to identify patients at
high- or low- risk for clinically manifest
CVC-related thrombosis, and focused early
intervention may be initiated.
Discussion and 
Future developments
The potential benefit from our studies,
concerning risk assessment and early identifi-
cation of patients at high-risk of CVC-relat-
ed thrombosis, needs still to be defined.
Clearly, in patients who receive routine anti-
coagulant prophylaxis (i.e. postoperative or
intensive care unit patients, patients with
therapeutic anticoagulants due to cardiac dis-
ease) additional risk stratification or screen-
ing is not beneficial. The risk of thrombosis
and secondary complications is too low to
justify additional measures. In addition, in
patients with a low-risk of thrombosis, anti-
coagulant prophylaxis may be safely with-
held. The groups who may benefit most
from individualized preventive measures are
those who have a substantial risk of manifest
thrombosis or complications (e.g. a risk >
10%), and those with substantial bleeding
risk (e.g. due to chemotherapy induced
thrombocytopenia). The clinical value, bene-
fit and safety of risk stratification of CVC-
related thrombosis and subsequent individu-
alized prophylaxis or surveillance needs to be
further explored.
An important issue in performing risk
stratification is which risk factors to include.
Those are preferably factors already known
before CVC insertion. In an ideal setting,
such parameters are also easy to determine,
of low-cost, safe and binary. Established risk
factors in venous thrombosis are commonly
known in the clinical field and are usually
easily determined by the history of patients,
e.g. oral contraceptives, obesity, personal his-
tory of thrombosis. FVL and prothrombin
G20210A (5-7% in the general population)
may also be included, since they clearly
enhance the risk of thrombosis. However,
measuring such factors should be carefully
implied, since they are genetic determinants
of blood coagulation and “labeling” patients
of heritable disease may have psychological
and social disadvantages. Firstly, knowledge
of the presence of thrombophilia should not
affect future treatment decisions in thrombo-
embolic disease; i.e. a patient might develop
proximal deep vein thrombosis of the leg in
the future. Secondly, patients should be pro-
tected against unjustified legal and insurance
issues. Other factors that influence decisions
on the initiation of prophylaxis and surveil-
lance could be the type of CVC, the degree
of vascular trauma, manipulation, and the
expected duration of catheterization. Since
the majority of adverse clinical complications
occur after the first 10 days of catheteriza-
tion, anticoagulant prophylaxis may only be
necessary in prolonged catheterization.
After insertion of a CVC, routine surveil-
lance may identify patients at increased risk
of clinically manifest thrombosis. However,
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several issues are still to be clarified. Firstly, it
should be investigated whether routine sur-
veillance affects clinical outcome. Serially
drawn surveillance cultures may be used to
identify patients at high-risk of manifest
thrombosis and to initiate early intervention.
Important issues in this strategy are the cut-
off point (number) of positive identical cul-
tures and the type of intervention (anticoag-
ulants, early CVC removal or replacement, or
both) possibly after additional diagnostic
imaging. Although screening ultrasound has
potential benefits, it is labor-intensive and
costly when performed on a weekly basis.
Ultrasound screening may therefore be
reserved for patients with CVC related infec-
tions, or to determine whether a CVC should
be removed, or to decide whether anticoagu-
lants should be started, in patients in whom
these interventions are (relatively) contra-
indicated. Ultrasound screening may also be
reduced to a limited single observation, to
reduce labor and costs. Whether a limited
screening-schedule is still beneficial is how-
ever unknown.
Finally, the assessment of the true inci-
dence of pulmonary embolism in CVC-relat-
ed thrombosis and the treatment of CVC-
related thrombosis were beyond the scope of
this thesis and are largely understudied.
Clearly, there is a clinical need for well-
designed studies addressing both issues.
105
Discussion and Future Developments
boek_inhoud.qxp  23-11-2005  21:09  Pagina 105
boek_inhoud.qxp  23-11-2005  21:09  Pagina 106
CHAPTER 9
Nederlandse Samenvatting (Dutch Summary)
boek_inhoud.qxp  23-11-2005  21:09  Pagina 107
Samenvatting
Bij patiënten die zijn opgenomen in het
ziekenhuis bestaat vaak de noodzaak tot het
inbrengen van een centrale infuuslijn. Deze
“centrale lijnen” kunnen worden gebruikt
voor verschillende indicaties: het toedienen
van vloeistoffen en medicatie (bijv. chemo-
therapie), reguleren van het hartritme, voor
dialyse en voor serieel bloedafnames bij de
patiënt. Tevens kan bij patiënten met har-
tritmestoornissen een pacemaker worden
ingebracht, waarbij geleidingsdraden via de
aderen worden geïmplanteerd. Hierbij kun-
nen complicaties optreden in de vorm van
trombose (stolselvorming). Naast het feit dat
trombose de functie kan belemmeren, kun-
nen patiënten ernstige klachten krijgen
(trombose-arm). Soms ontstaat een levens-
bedreigende situatie als er een infectie
ontstaat of wanneer een stolsel losschiet en
zich verplaatst door de bloedsomloop naar
de longen (longembolie).
Met betrekking tot trombose bij centrale
lijnen bestaat nog een groot aantal vragen,
waarop in het huidige onderzoek wordt inge-
gaan. In dit onderzoek wordt het vóórkomen
en het risico van centrale lijnen trombose
beschreven. Daarnaast wordt inzicht gegeven
in de bijdrage van genetische en verworven
risicofactoren van trombose. Het goed kun-
nen schatten van het risico van trombose is
belangrijk in de dagelijkse praktijk. Bij
patienten met een “hoog-risico” op het krij-
gen van een trombosearm kunnen preven-
tieve maatregelen genomen worden om
trombose en complicaties daarvan te
voorkomen. Dit kan in de vorm van profy-
laxe met antistollingsmidel. Echter, bij som-
mige patiënten wordt het risico van bijwerk-
ing van deze antistolling te hoog geacht
(bloedingsrisico), bijvoorbeeld bij patiënten
die net een kuur chemotherapie hebben
ondergaan en daarom een laag gehalte aan
bloedplaatjes hebben. In de praktijk kan dit
een reden zijn van profylaxe met antistolling
af te zien.
Uit het huidige onderzoek blijkt dat bij
patiënten met een centrale lijn, trombose in
ongeveer 30% van alle patiënten met een
centrale lijn voorkomt. Vaak leidt trombose
echter niet tot klachten of complicaties. Van
alle patiënten met een centrale lijn blijkt 7%
klachten te krijgen (25% van de patiënten
met trombose). Tevens blijkt dat bij patiën-
ten met een zogenaamde erfelijke afwijkende
stollingsfactor in het bloed (factor V Leiden,
protrombine mutatie) het risico van trom-
bose 2 tot 3 keer meer toeneemt (van
ongeveer 30% naar 70%). Daarnaast is het
eerder gehad hebben van een trombose
(bijvoorbeeld trombosebeen) een belangrijke
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risicofactor. Kankerpatiënten die chemother-
apie krijgen blijken een grotere kans te
hebben op symptomen van trombose (ern-
stige pijnklachten of zwelling van de arm)
dan andere patiënten.
Patiënten met pacemakers of defibrilla-
tors kunnen ook te maken krijgen met trom-
bose. Deze ontstaat als gevolg van het
inbrengen van een geleidingsdraad, inge-
bracht via de ader onder het sleutelbeen. In
vergelijking met patiënten met een centrale
lijn hebben patiënten met pacemakers min-
der kans op trombose (22%). Ook zijn com-
plicaties van trombose bij deze patiënten zeer
zeldzaam. In deze groep patiënten zijn de
twee belangrijkste risicofactoren: het niet 
krijgen van antistolling en hormoongebruik
(bijv. “de pil”). Zeer waarschijnlijk speelt het
volledig onderhuids plaatsen van het systeem
ook een beschermende rol (minder manipu-
latie en minder infectiegevaar).
Na het inbrengen van een centrale lijn
kan bij patienten die een hoog risico hebben
op het krijgen van een trombose-arm het
nuttig zijn te screenen met echografie op
vroege stolselvorming of routinematig te
kweken van vloeistof afgenomen vanuit de
centrale lijn. In het geval dat er sprake is van
vroege stolselvorming blijkt het risico van
klachten of complicaties van trombose een
factor 7 toe te nemen. Ook bestaat er een
nauwe relatie tussen centrale lijn gerelateerde
trombose en infectie. Routinematig kweken
van vloeistof uit de centrale lijn blijkt soms
een trombose-arm te kunnen voorspellen in
33-71% van de gevallen (afhankelijk van de
hoeveelheid positieve kweken). Of vroeg-
tijdige behandeling gebaseerd op screenen
met echo of routinematig kweken van
catheter vloeistof, bijvoorbeeld door antis-
tolling of door vroegtijdige lijn verwijdering
of wisseling, ook effectief is, kan op dit
moment niet worden gezegd en zal in de
toekomst verder moeten worden onderzocht.
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